<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Cell Dev. Biol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Cell and Developmental Biology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Cell Dev. Biol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">2296-634X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1730542</article-id>
<article-id pub-id-type="doi">10.3389/fcell.2025.1730542</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A switch from &#x3b1;5&#x3b2;1 to &#x3b1;v&#x3b2;3 integrin activity contributes to the development of a profibrotic mesenchymal phenotype in trabecular meshwork cells</article-title>
<alt-title alt-title-type="left-running-head">Johns et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fcell.2025.1730542">10.3389/fcell.2025.1730542</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Johns</surname>
<given-names>Kassidy L.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Faralli</surname>
<given-names>Jennifer A.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3289578"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal Analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Filla</surname>
<given-names>Mark S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shah</surname>
<given-names>Nandini</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Keller</surname>
<given-names>Kate E.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1338197"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Peters</surname>
<given-names>Donna M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1344615"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &#x26; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/">Writing - review and editing</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Department of Pathology &#x26; Laboratory Medicine, University of Wisconsin School of Medicine and Public Health</institution>, <city>Madison</city>, <state>WI</state>, <country country="US">United States</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>Casey Eye Institute, Oregon Health &#x26; Science University</institution>, <city>Portland</city>, <state>OR</state>, <country country="US">United States</country>
</aff>
<aff id="aff3">
<label>3</label>
<institution>Department of Ophthalmology &#x26; Visual Sciences, University of Wisconsin School of Medicine and Public Health</institution>, <city>Madison</city>, <state>WI</state>, <country country="US">United States</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: Donna M. Peters, <email xlink:href="mailto:dmpeter2@wisc.edu">dmpeter2@wisc.edu</email>
</corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-30">
<day>30</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>1730542</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>10</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>09</day>
<month>12</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>12</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Johns, Faralli, Filla, Shah, Keller and Peters.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Johns, Faralli, Filla, Shah, Keller and Peters</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-30">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Purpose</title>
<p>Fibrogenic changes in the trabecular meshwork (TM) are considered to be a major cause for the restriction in aqueous humor outflow from the anterior chamber associated with primary open angle glaucoma. In this study, we investigated whether integrin switching from &#x3b1;5&#x3b2;1 to &#x3b1;v&#x3b2;3 integrin expression could initiate fibrotic-like changes in the TM that could restrict outflow.</p>
</sec>
<sec>
<title>Methods</title>
<p>Human TM cells were isolated from young (&#x3c;40&#xa0;years) and old (&#x3e;50&#xa0;years) donor eyes. RT-PCR, western blots and immunofluorescence microscopy were used to evaluate levels of integrin and &#x3b1;SMA expression. Lentiviral shRNA vectors were used to knockdown &#x3b1;5 and &#x3b2;3 integrin levels. Paraffin embedded anterior segments of young and old donor eyes were used to evaluate &#x3b1;SMA levels <italic>in situ</italic>.</p>
</sec>
<sec>
<title>Results</title>
<p>Studies revealed an age-related decrease in &#x3b1;5 integrin mRNA expression in TM cells. This loss was accompanied by an increase in &#x3b1;SMA mRNA and protein levels and an increase in activated &#x3b1;v&#x3b2;3 integrin levels. Knockdown of &#x3b2;3 integrin mRNA and protein levels decreased the expression of &#x3b1;SMA mRNA and protein levels. Elevated mRNA levels of the EndMT biomarkers, <italic>VIM</italic>, <italic>SNAI2</italic>, and <italic>TWIST1</italic>, observed in older TM cells were decreased when &#x3b2;3 integrin was knockdown.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>These studies suggest that crosstalk between &#x3b1;5&#x3b2;1 and &#x3b1;v&#x3b2;3 integrin signaling controls expression of &#x3b1;SMA mRNA and protein levels and that &#x3b2;3 integrins may play a role in the development of the fibrogenic phenotype in TM cells and associated with POAG.</p>
</sec>
</abstract>
<kwd-group>
<kwd>aging</kwd>
<kwd>contractility</kwd>
<kwd>EndMT</kwd>
<kwd>integrins</kwd>
<kwd>trabecular meshwork</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. This study was supported by NIH grants R01EY017006 (DMP), R01EY032905 (DMP), P30 EY016665 core facility at that University of Wisconsin at Madison and EY032590 (KEK), EY019643 (KEK), and P30 EY010572 core facility grant at Casey Eye Institute, Oregon Health &#x26; Science University.</funding-statement>
</funding-group>
<counts>
<fig-count count="9"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="77"/>
<page-count count="18"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Molecular and Cellular Pathology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<title>Introduction</title>
<p>Glaucoma is a family of optic neuropathies that result in irreversible optic nerve damage. It is the major cause of irreversible blindness worldwide. Nearly 76 million people have the disease, including &#x3e;4 million in the United States (<xref ref-type="bibr" rid="B70">Tham et al., 2014</xref>; <xref ref-type="bibr" rid="B10">Ehrlich et al., 2024</xref>). In the United States, primary open-angle glaucoma (POAG) is the most common form of glaucoma. Like many other chronic age-related diseases, there is increasing evidence that fibrotic-like changes play a role in the pathogenesis of POAG. These changes are a consequence of cell-specific factors that result in unresolved inflammatory responses, uncontrolled remodeling of the extracellular matrix (ECM) and senescence or cell loss (<xref ref-type="bibr" rid="B63">Selman and Pardo, 2021</xref>; <xref ref-type="bibr" rid="B21">Filla et al., 2021</xref>). They are considered the primary cause for the elevation in intraocular pressure (IOP), a major risk factor in the development of POAG that if uncontrolled will damage the optic nerve leading to retinal ganglion cell death and ultimately causing blindness. In POAG, these fibrotic-like changes occur within the trabecular meshwork (TM), specifically within the juxtacanalicular tissue (JCT) and inner wall of Schlemm&#x2019;s Canal (SC). The TM is a critical regulator of IOP as it acts as a pulsatile pump that controls the movement of aqueous humor (AH) out of the anterior chamber (<xref ref-type="bibr" rid="B36">Johnstone et al., 2021</xref>). Fibrotic-like changes during aging are thought to make the TM tissue stiffer (<xref ref-type="bibr" rid="B46">Last et al., 2011</xref>; <xref ref-type="bibr" rid="B66">Stamer et al., 2015</xref>) thereby causing the pulsatile properties of the TM to malfunction resulting in an elevation in IOP (<xref ref-type="bibr" rid="B36">Johnstone et al., 2021</xref>).</p>
<p>A major cause for these fibrogenic changes in the TM is thought to be elevated levels of transforming growth factor-&#x3b2;2 (TGF&#x3b2;2) in aqueous humor. (<xref ref-type="bibr" rid="B23">Fuchshofer and Tamm, 2012</xref>; <xref ref-type="bibr" rid="B47">Li et al., 2022</xref>). Greater than half of POAG patients have elevated TGF&#x3b2;2 levels in their aqueous humor (<xref ref-type="bibr" rid="B71">Tripathi et al., 1994</xref>; <xref ref-type="bibr" rid="B57">Picht et al., 2001</xref>; <xref ref-type="bibr" rid="B68">Tan et al., 2024</xref>). These changes are associated with a process called endothelial-to-mesenchymal transition (EndMT) that results in the development of a myofibroblastic phenotype (<xref ref-type="bibr" rid="B34">Islam et al., 2021</xref>; <xref ref-type="bibr" rid="B75">Yang et al., 2025</xref>). EndMT is characterized by the upregulated expression of specific cellular biomarkers, such as snail, twist, &#x3b1;-smooth muscle actin (&#x3b1;SMA), and vimentin, increased levels of ECM molecules, such as the EDA &#x2b; isoform of fibronectin (EDA &#x2b; FN) and collagen types I and IV, as well as the expression of the cytokines TGF&#x3b2; and connective tissue growth factor (CTGF). Transition into this phenotype occurs in stages (<xref ref-type="bibr" rid="B11">Fang et al., 2021</xref>) and involves a constellation of signaling pathways including cell-matrix interactions with integrins (<xref ref-type="bibr" rid="B51">Machado-Costa et al., 2020</xref>).</p>
<p>Integrins are a family of receptors that sense changes in the mechanobiological environment of cells and act as critical modulators of processes that control outflow facility and IOP. These processes include the assembly and remodeling of the ECM (<xref ref-type="bibr" rid="B64">Singh et al., 2010</xref>; <xref ref-type="bibr" rid="B67">Sun et al., 2025</xref>), the contraction forces of the cellular actomyosin network (<xref ref-type="bibr" rid="B69">Tang and Anfinogenova, 2009</xref>; <xref ref-type="bibr" rid="B61">Roca-Cusachs et al., 2012</xref>) and the phagocytic properties of TM&#xa0;cells (<xref ref-type="bibr" rid="B9">Dupuy and Caron, 2008</xref>; <xref ref-type="bibr" rid="B24">Gagen et al., 2013</xref>; <xref ref-type="bibr" rid="B56">Peotter et al., 2016</xref>). To date, 14 different integrins have been identified in the TM tissue where they are localized throughout the TM, JCT and SC regions of the outflow pathway (<xref ref-type="bibr" rid="B14">Faralli et al., 2019b</xref>; <xref ref-type="bibr" rid="B73">van Zyl et al., 2020</xref>). The activity of integrins is tightly regulated by their conformation. An inactive integrin has a bent conformation while an active integrin is in an upright conformation and can engage ECM proteins, form focal adhesions, trigger actin polymerization and regulate several signal transduction pathways. Integrins rapidly fluctuate between active and inactive conformations in response to environmental conditions present in the TM such as pressure, stretch, and ECM composition, all of which can be altered in POAG (<xref ref-type="bibr" rid="B65">Stamer and Acott, 2012</xref>; <xref ref-type="bibr" rid="B19">Filla et al., 2017</xref>; <xref ref-type="bibr" rid="B41">Kechagia et al., 2019</xref>; <xref ref-type="bibr" rid="B36">Johnstone et al., 2021</xref>; <xref ref-type="bibr" rid="B42">Keller and Peters, 2022</xref>).</p>
<p>Numerous studies have shown that crosstalk between different integrins regulates their expression and activity (<xref ref-type="bibr" rid="B8">Diaz-Gonzalez et al., 1996</xref>; <xref ref-type="bibr" rid="B44">Kim et al., 2011</xref>; <xref ref-type="bibr" rid="B15">Faralli et al., 2022</xref>). Hence any change or loss in integrin expression, often referred to as integrin switching, is likely to affect the activity of existing integrins on the cell surface (<xref ref-type="bibr" rid="B52">Madamanchi et al., 2014</xref>) and, in some instances, contribute to an EndMT phenotype (<xref ref-type="bibr" rid="B72">Truong et al., 2014</xref>; <xref ref-type="bibr" rid="B60">Rapisarda et al., 2017</xref>). Recent studies have suggested that a switch in integrin expression and activity may be occurring in some aging TM&#xa0;cells and contributing to the development of a fibrogenic phenotype. These studies showed that an age-related loss of &#x3b1;5&#x3b2;1 integrin expression on the TM cell surface contributed to an increase in activity of the &#x3b1;v&#x3b2;3 integrin (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>). Cells expressing activated &#x3b1;v&#x3b2;3 integrin were found to be more contractile and assembled &#x3b1;SMA into robust stress fibers. A comparison of &#x3b1;v&#x3b2;3 integrin expression in glaucomatous TM cells and aged matched normal TM cells also showed more intense staining of &#x3b1;v&#x3b2;3 integrin in focal adhesions in glaucomatous cells (<xref ref-type="bibr" rid="B75">Yang et al., 2025</xref>). These focal adhesions were larger and reminiscent of supermature focal adhesions observed in myofibroblasts associated with a fibrotic phenotype (<xref ref-type="bibr" rid="B30">Hinz, 2010</xref>; <xref ref-type="bibr" rid="B31">Hinz and Gabbiani, 2010</xref>). Finally, over expression of the active &#x3b1;v&#x3b2;3 integrin increased the expression of the profibrotic genes associated with TGF&#x3b2;2-induced glaucoma (<xref ref-type="bibr" rid="B19">Filla et al., 2017</xref>; <xref ref-type="bibr" rid="B15">Faralli et al., 2022</xref>; <xref ref-type="bibr" rid="B16">Faralli et al., 2023</xref>).</p>
<p>Among the integrins in the TM, the &#x3b1;v&#x3b2;3 integrin is most likely to be involved in POAG (<xref ref-type="bibr" rid="B73">van Zyl et al., 2020</xref>; <xref ref-type="bibr" rid="B19">Filla et al., 2017</xref>; <xref ref-type="bibr" rid="B77">Zhou et al., 1999</xref>). The &#x3b1;v&#x3b2;3 integrin is mostly concentrated in the inner wall of SC and the JCT, which is the primary site of resistant for aqueous humor outflow. The activity of &#x3b1;v&#x3b2;3 integrin triggers many of the common changes associated with POAG (<xref ref-type="bibr" rid="B19">Filla et al., 2017</xref>; <xref ref-type="bibr" rid="B56">Peotter et al., 2016</xref>). The transition into a myofibroblast phenotype is often preceded by the activation of &#x3b1;v&#x3b2;3 integrin (<xref ref-type="bibr" rid="B31">Hinz and Gabbiani, 2010</xref>; <xref ref-type="bibr" rid="B33">Hinz et al., 2019</xref>; <xref ref-type="bibr" rid="B16">Faralli et al., 2023</xref>; <xref ref-type="bibr" rid="B28">Goffin et al., 2006</xref>; <xref ref-type="bibr" rid="B30">Hinz, 2010</xref>). The knockdown of &#x3b1;v&#x3b2;3 integrin decreased IOP in mice and activation of it increased IOP in both a porcine organ culture perfusion model and mice <italic>in vivo</italic> (<xref ref-type="bibr" rid="B13">Faralli et al., 2019a</xref>; <xref ref-type="bibr" rid="B21">Filla et al., 2021</xref>). Activation of &#x3b1;v&#x3b2;3 integrin signaling also increases the deposition of EDA&#x2b;FN into the ECM and the expression of TGF&#x3b2;2 in TM cultures, both factors involved in POAG (<xref ref-type="bibr" rid="B20">Filla et al., 2019</xref>; <xref ref-type="bibr" rid="B21">Filla et al., 2021</xref>). It can also serve as a receptor for the growth factor CTGF, a downstream target of TGF&#x3b2;2 in the TM that can upregulate IOP (<xref ref-type="bibr" rid="B39">Junglas et al., 2012</xref>; <xref ref-type="bibr" rid="B38">Junglas et al., 2009</xref>; <xref ref-type="bibr" rid="B29">Hennig et al., 2016</xref>). In addition, studies show that &#x3b1;v&#x3b2;3 integrin is part of a secondary glucocorticoid (GC) response in GC-induced-glaucoma that regulates the formation of cross-linked actin networks (CLANs) and phagocytosis (<xref ref-type="bibr" rid="B18">Filla et al., 2009</xref>; <xref ref-type="bibr" rid="B17">Filla et al., 2006</xref>; <xref ref-type="bibr" rid="B12">Faralli et al., 2013</xref>; <xref ref-type="bibr" rid="B24">Gagen et al., 2013</xref>). Finally, studies have shown that its activity is associated with hic-5, a transcription factor involved in the TGF&#x3b2;2-induced fibrogenic response in human TM cells (<xref ref-type="bibr" rid="B55">Pattabiraman and Rao, 2015</xref>).</p>
<p>In this study, we used human TM&#xa0;cells to investigate if switching integrin expression from &#x3b1;5&#x3b2;1 to &#x3b1;v&#x3b2;3 impacts the development of a myofibroblast phenotype. Using shRNA lentiviral particles to knockdown expression of &#x3b1;5 or &#x3b2;3 integrins, these studies show that the expression of &#x3b1;SMA was dependent on both the level of &#x3b1;5 integrin mRNA and the activity of the &#x3b1;v&#x3b2;3 integrin. When &#x3b1;5 integrin mRNA levels were high in young TM&#xa0;cells, we found that the expression of &#x3b1;SMA and the formation of &#x3b1;SMA stress fibers in TM&#xa0;cells was downregulated. In contrast, low levels of &#x3b1;5 integrin mRNA in TM cells triggered an increase in &#x3b1;SMA expression and stress fiber formation as well as an increase in the activated levels of &#x3b1;v&#x3b2;3 integrin. In addition, there was an increase in the mRNA levels for EndMT biomarkers (<italic>VIM</italic>, <italic>SNAI2</italic>, and <italic>TWIST1</italic>). Conversely, low levels of &#x3b2;3 integrin mRNA in old TM&#xa0;cells caused a decrease in &#x3b1;SMA stress fibers and in the mRNA levels for <italic>&#x3b1;SMA</italic>, <italic>VIM</italic>, <italic>SNAI2</italic>, and <italic>TWIST1.</italic> Together, these studies suggest that integrin switching could be an early step in the development of the fibrotic-like phenotype associated with POAG.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and methods</title>
<sec id="s2-1">
<title>Cell culture</title>
<p>Human TM cells were isolated in accordance with the tenets of the Declaration of Helsinki from corneal rims or whole globes of cadaver eyes as previously described (<xref ref-type="bibr" rid="B17">Filla et al., 2006</xref>). Human tissue experiments complied with the guidelines of the ARVO Best Practices for Using Human Eye Tissue in Research (November 2021). Donor eyes and corneal rims were obtained from both the Lions Eye Bank of Wisconsin and VisionGift, Portland, OR. Tissues from both males and females were used and all donors were Caucasian with no known history of glaucoma or other ocular diseases. The sex, age, and cause of death of specific donors has been previously published (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>). All the TM cell strains were judged to be TM cells based upon criteria previously described (<xref ref-type="bibr" rid="B43">Keller et al., 2018</xref>) and the upregulation of myocilin expression in response to dexamethasone was confirmed (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>). Cells were grown in low glucose Dulbecco&#x2019;s Modified Eagle&#x2019;s Medium (DMEM Sigma-Aldrich) supplemented with 15% fetal bovine serum (FBS, Avantor-VWR), 2% L-glutamine (Sigma-Aldrich), 1% amphotericin B (Corning), 0.05% gentamycin (Sigma-Aldrich), and 1&#xa0;ng/mL FGF-2 (Peprotech) and used between passages 5 and 8. <xref ref-type="table" rid="T1">Table 1</xref> shows the cell strains used in this study and the percentage of cells in each strain expressing &#x3b1;5 integrin at the cell surface as determined by flow cytometry.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Percentage of TM cells containing &#x3b1;5 integrin on cell surface. Donor nomenclature refers to nomenclature used in previous publication (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>)</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Cell strain</th>
<th align="left">Donor</th>
<th align="left">Gender</th>
<th align="left">Age of donor</th>
<th align="left">&#x3b1;5 integrin positive cells (%)</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">N17</td>
<td align="left">N17RM.1</td>
<td align="left">Male</td>
<td align="left">17</td>
<td align="left">91</td>
</tr>
<tr>
<td align="left">N21</td>
<td align="left">2021-0755</td>
<td align="left">Female</td>
<td align="left">21</td>
<td align="left">96</td>
</tr>
<tr>
<td align="left">N25</td>
<td align="left">N25LM8.1</td>
<td align="left">Male</td>
<td align="left">25</td>
<td align="left">98</td>
</tr>
<tr>
<td align="left">N27</td>
<td align="left">N27TM-6</td>
<td align="left">Female</td>
<td align="left">27</td>
<td align="left">89</td>
</tr>
<tr>
<td align="left">N27-2</td>
<td align="left">N27TM-2</td>
<td align="left">Female</td>
<td align="left">27</td>
<td align="left">94</td>
</tr>
<tr>
<td align="left">N35</td>
<td align="left">N35LM8.1</td>
<td align="left">Male</td>
<td align="left">35</td>
<td align="left">98</td>
</tr>
<tr>
<td align="left">N36</td>
<td align="left">2017-0509</td>
<td align="left">Male</td>
<td align="left">36</td>
<td align="left">93</td>
</tr>
<tr>
<td align="left">N55</td>
<td align="left">2018-1341</td>
<td align="left">Male</td>
<td align="left">55</td>
<td align="left">99</td>
</tr>
<tr>
<td align="left">N57</td>
<td align="left">2021-1323</td>
<td align="left">Male</td>
<td align="left">57</td>
<td align="left">92</td>
</tr>
<tr>
<td align="left">N69</td>
<td align="left">2020-0984</td>
<td align="left">Male</td>
<td align="left">69</td>
<td align="left">96</td>
</tr>
<tr>
<td align="left">N71</td>
<td align="left">N71LF3</td>
<td align="left">Female</td>
<td align="left">71</td>
<td align="left">88</td>
</tr>
<tr>
<td align="left">N74</td>
<td align="left">2021-1493</td>
<td align="left">Female</td>
<td align="left">74</td>
<td align="left">40</td>
</tr>
<tr>
<td align="left">N75</td>
<td align="left">2021-1328</td>
<td align="left">Male</td>
<td align="left">75</td>
<td align="left">98</td>
</tr>
<tr>
<td align="left">N77</td>
<td align="left">2022-0140</td>
<td align="left">Female</td>
<td align="left">77</td>
<td align="left">51</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-2">
<title>RNA isolation and RT-qPCR</title>
<p>Total RNA was isolated from TM cells using RNeasy Plus Mini Kit (Qiagen Inc, Germantown, MD), or TRIzol (Invitrogen), and reversed transcribed into cDNA using the High-capacity cDNA reverse transcription kit (Applied Biosystems, Waltham, MA) according to the manufacturer&#x2019;s instructions. RT-qPCR was performed using an Applied Biosystems QuantStudio 6 Pro Real-Time PCR system and PowerUp SYBR green master mix (Thermo Fisher Scientific). Primers that spanned an intron-exon junction when possible were designed using the primer-BLAST program (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/tools/primer-blast/">https://www.ncbi.nlm.nih.gov/tools/primer-blast/</ext-link>). All primers were made by IDT (Coralville, IA). The sequences of the primers are shown in <xref ref-type="table" rid="T2">Table 2</xref>.</p>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Primers used for RT-qPCR. All sequences are given in the 5&#x2032; to 3&#x2032; direction.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Gene</th>
<th align="left">Reverse sequence</th>
<th align="left">Forward sequence</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">HPRT1</td>
<td align="left">GGT&#x200b;CCT&#x200b;TTT&#x200b;CAC&#x200b;CAG&#x200b;CAA&#x200b;GCT</td>
<td align="left">TGA&#x200b;CAC&#x200b;TGG&#x200b;CAA&#x200b;AAC&#x200b;AAT&#x200b;GCA</td>
</tr>
<tr>
<td align="left">ITGB3 (&#x3b2;3 integrin)</td>
<td align="left">TTC&#x200b;TTC&#x200b;GAA&#x200b;TCA&#x200b;TCT&#x200b;GGC&#x200b;C</td>
<td align="left">GTG&#x200b;ACC&#x200b;TGA&#x200b;AGG&#x200b;AGA&#x200b;ATC&#x200b;TGC</td>
</tr>
<tr>
<td align="left">ITGA5 (&#x3b1;5 integrin)</td>
<td align="left">GTGGCCACCTGACGCTCT</td>
<td align="left">TGC&#x200b;AGT&#x200b;GTG&#x200b;AGG&#x200b;CTG&#x200b;TGT&#x200b;ACA</td>
</tr>
<tr>
<td align="left">VIM</td>
<td align="left">TAC&#x200b;AGG&#x200b;AAG&#x200b;CTG&#x200b;CTG&#x200b;GAA&#x200b;GG</td>
<td align="left">ACC&#x200b;AGA&#x200b;GGG&#x200b;AGT&#x200b;GAA&#x200b;TCC&#x200b;AG</td>
</tr>
<tr>
<td align="left">SNAI1</td>
<td align="left">TGCGTCTGCGGAACCTG</td>
<td align="left">GGA&#x200b;CTC&#x200b;TTG&#x200b;GTG&#x200b;CTT&#x200b;GTG&#x200b;GA</td>
</tr>
<tr>
<td align="left">SNAI2</td>
<td align="left">ACC&#x200b;CCA&#x200b;CAT&#x200b;CCT&#x200b;TCT&#x200b;CAC&#x200b;TG</td>
<td align="left">CCGACAAGTGACAGCCAT</td>
</tr>
<tr>
<td align="left">TWIST1</td>
<td align="left">AAG&#x200b;GCA&#x200b;TCA&#x200b;CTA&#x200b;TGG&#x200b;ACT&#x200b;TTC</td>
<td align="left">GCC&#x200b;AGT&#x200b;TTG&#x200b;ATC&#x200b;CCA&#x200b;GTA&#x200b;TTT&#x200b;T</td>
</tr>
<tr>
<td align="left">ACTA2 (&#x3b1;SMA)</td>
<td align="left">GTG&#x200b;TTG&#x200b;CCC&#x200b;CTG&#x200b;AAG&#x200b;AGC&#x200b;AT</td>
<td align="left">GCT&#x200b;GGG&#x200b;ACA&#x200b;TTG&#x200b;AAA&#x200b;GTC&#x200b;TCA</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-3">
<title>Immunofluorescence microscopy</title>
<p>TM cells were plated onto coverslips pre-coated with 5&#xa0;&#xb5;g/mL plasma fibronectin or 40&#xa0;&#xb5;g/mL human type I collagen (Millipore Sigma) at a density of 3 &#xd7; 10<sup>4</sup> cells/well as previously described (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>). After 3&#xa0;h, cells were fixed with 2% paraformaldehyde in phosphate buffered saline (PBS) for 20&#xa0;min and then permeabilized with 0.1% Triton X-100 in PBS for 10&#xa0;min. The cells were blocked with 1% BSA in PBS for 30&#xa0;min, labeled with mouse primary monoclonal antibodies [BV3] (Abcam, &#x23;ab7166; RRID: AB_305742) at 1&#xa0;&#xb5;g/mL or LIBS2 (Millipore-Sigma, &#x23;MABT27; RRID: AB_10806476) at 10&#xa0;&#xb5;g/mL for 1&#xa0;h at room temperature. The primary antibodies were detected using a 1:500 dilution of Alexa 546-conguated goat anti-mouse IgG (ThermoFisher Scientific). A 1:300 dilution of Alexa 488-conjugated phalloidin was used during this step to detect F-actin (ThermoFisher Scientific). Hoechst 33342&#xa0;at 1&#xa0;&#xb5;g/mL was used to label nuclei. Coverslips were mounted onto slides using Shandon&#x2122; Immu-mount (ThermoFisher Scientific) and cells were imaged using a Zeiss Imager M2 fluorescence microscope together with the Zen image acquisition software version 3.079.</p>
<p>To detect &#x3b1;SMA, TM cells were fixed and permeabilized with ice-cold methanol for 15&#xa0;min at &#x2212;20&#xa0;&#xb0;C and then blocked in 1% BSA in PBS (1% BSA/PBS) for 30&#xa0;min at room temperature. Fixed cells were labeled with rabbit anti-&#x3b1;-SMA antibody (Abcam, &#x23;ab5694; RRID: AB_2223021) at 2&#xa0;&#xb5;g/mL for 1&#xa0;h at room temperature followed by a 1:500 dilution of Alexa 546-conguated goat anti-rabbit IgG for 30&#xa0;min at room temperature. Cells were labeled with Hoechst 33342 to detect nuclei. Coverslips were mounted and imaged as described above. Relative fluorescence intensity was measured using Zeiss software (Zen version 3.079).</p>
</sec>
<sec id="s2-4">
<title>Flow cytometry</title>
<p>Levels of &#x3b1;5, &#x3b1;v&#x3b2;3 and active &#x3b1;v&#x3b2;3 integrin on the TM&#xa0;cell surface were measured as previously described (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>). Briefly, TM&#xa0;cells were lifted with Cell Dissociation Solution Non-enzymatic (Sigma-Aldrich Corp.), blocked for 30&#xa0;min on ice with 1% BSA in PBS and labeled for 1&#xa0;h on ice with 10&#xa0;&#x3bc;g/mL &#x3b1;5 (P1D6, ThermoFisher Scientific, &#x23;12-4900-42, RRID:AB_10717080), total &#x3b1;v&#x3b2;3 (LM609, Sigma-Millipore, mAb 1976, RRID:AB_2296419), and active &#x3b1;v&#x3b2;3 (LIBS2, Millipore Sigma, MABT27, RRID:AB_10806476) integrin antibodies in 1% BSA/PBS. This was followed by a secondary Alexa 647-conjugated rabbit anti-mouse IgG (Thermo Fisher Scientific) diluted 1:400 in 1% BSA/PBS for 45&#xa0;min on ice. Labeled cells were washed, resuspended in 1%BSA/PBS, strained with a 40&#x2013;70&#xa0;&#x3bc;m strainer to remove clumps and analyzed with the Cytek NL-3000 flow cytometer (Cytec Biosciences, Fremont, CA, USA) and the SpectroFlo program. Flow-Jo version 10.1 was used to analyze and graph the results. Unlabeled cells in 1% BSA/PBS were used as a control for autofluorescence.</p>
</sec>
<sec id="s2-5">
<title>Immunolabeling of anterior segments for &#x3b1;SMA and &#x3b1;5 integrin</title>
<p>Wedges of anterior segments were cut, fixed with 4% paraformaldehyde in PBS, and embedded in paraffin as previously described (<xref ref-type="bibr" rid="B22">Filla et al., 2023</xref>). None of the donor tissues had a history of glaucoma. Sagittal tissue sections 5&#xa0;&#xb5;m thick were cut and deparaffinized in xylenes and rehydrated through a series of 100%&#x2013;50% ethanol solutions. For &#x3b1;SMA labeling, antigen retrieval was performed on the sections using 0.05% trypsin in PBS at 37&#xa0;&#xb0;C for 20&#xa0;min. For &#x3b1;5 integrin labeling, 95&#xa0;&#xb0;C antigen retrieval was performed using R-Universal epitope recovery buffer (Electron Microscopy Sciences, Hatfield, PA). Sections were blocked with 1% BSA in PBS and labeled overnight at 4&#xa0;&#xb0;C with 1&#xa0;&#xb5;g/mL mouse anti-&#x3b1;SMA monoclonal antibody ASM-1 (Sigma-Millipore, &#x23;CBL 171; RRID: AB_2223166) or 4&#xa0;&#xb5;g/mL mouse anti-&#x3b1;5 integrin monoclonal antibody 10F6 (ThermoFisher Scientific, &#x23;MA5-15568; RRID:AB_10979290). Sections labeled with either 1 or 4&#xa0;&#xb5;g/mL mouse anti-&#x3b2;-galactosidase monoclonal antibody GAL-13 (Sigma-Millipore, &#x23;G8021; RRID:AB_259970) were used as negative controls to confirm specificity of the labeling for &#x3b1;SMA and &#x3b1;5 integrin, respectively. The primary antibodies were detected using a 1:500 dilution of Alexa 546-conjugated goat anti-mouse IgG (ThermoFisher, Scientific, &#x23;A-11030). Nuclei were labeled with Hoechst 33342 at 1&#xa0;&#xb5;g/mL. Sections were mounted onto glass coverslips using Shandon&#x2122; Immu-mount. Labeled sections were imaged as described above.</p>
</sec>
<sec id="s2-6">
<title>Lentiviral shRNA knockdown of &#x3b1;5 or &#x3b2;3 integrin</title>
<p>TM cells were plated at a density of 5 &#xd7; 10<sup>4</sup> cells/2.8&#xa0;cm<sup>2</sup> and grown to 70%&#x2013;80% confluency. Cells were then transduced using a MOI of 50, 100 or 150 with either a &#x3b1;5 integrin shRNA lentiviral vector (MISSION&#xae; lentiviral particles clone ID TRCN0000029653, Sigma-Aldrich), or &#x3b2;3 integrin shRNA lentiviral vector (Mission&#xae; lentiviral particles clone ID TRCN0000003235, Sigma-Aldrich). Non-targeting lentiviral particles (MISSION&#xae;lentiviral particles &#x23;SHC016VN, Sigma-Aldrich) as well as untransduced cells were used as controls. These controls are referred to as Con-NT and Con-UT, respectively. Twenty-four hours later, transduced cells were selected using 1.5&#xa0;mg/mL G418 sulfate (Corning, 61-234-RG). Transduced cells were maintained under selection for the duration of the experiments. Seventy-two hours after transduction, some transduced cells were harvested for RNA and used for RT-qPCR analysis as described above. RT-qPCR was performed using primers against &#x3b1;5 integrin, &#x3b2;3 integrin, &#x3b1;SMA, and HPRT1 for the housekeeping gene (<xref ref-type="table" rid="T2">Table 2</xref>). Cells that were not transduced were also used as a control.</p>
</sec>
<sec id="s2-7">
<title>Western blot analysis</title>
<p>Six days after transduction, TM cells were lysed with 25&#xa0;mM HEPES, pH 7.4 buffer containing 150&#xa0;mM NaCl, 1&#xa0;mM EDTA, 1&#xa0;mM NaF, 1% NP-40, 0.25% deoxycholate, HALT phosphatase inhibitor cocktail, and HALT protease inhibitor cocktail (Thermo Fisher Scientific, Inc.) as previously described (<xref ref-type="bibr" rid="B12">Faralli et al., 2013</xref>; <xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>). Cell lysates were clarified by centrifugation at 10,000 &#xd7; g for 10&#xa0;min at 4&#xa0;&#xb0;C and run on 10%-SDS-PAGE gels. Proteins were then transferred to a nitrocellulose membrane (Bio-Rad Laboratories). The membranes were blocked overnight at 4&#xa0;&#xb0;C with 3% BSA in 20&#xa0;mM Tris pH 7.4, 150&#xa0;mM NaCl (TBS) buffer and then incubated with a primary antibody in 1% BSA/TBS/0.1% Tween-20 for 1&#xa0;h at room temperature. Primary antibodies used were rabbit anti-&#x3b1;5 integrin (Cell Signaling Technology, Cat &#x23; 4705S, RRID:AB_2233962, 1:1000), rabbit anti-&#x3b1;SMA (Abcam, &#x23;ab5694; RRID: AB_2223021), 1:250, rabbit anti-&#x3b2;3 integrin (Cell Signaling Technology clone D7X3P, cat &#x23;13166S; RRID:AB_2798136, 1:1000) and rabbit anti-GAPDH (Abcam cat &#x23; 9485; RRID: AB_307275, 1:2500). Membranes were washed with TBS/0.1% Tween-20 and incubated for 1&#xa0;h with a secondary antibody (LI-COR Biosciences, Lincoln, NE, USA, IRDye 800CW goat &#x3b1;-rabbit or mouse, 1:15000). Labeled bands were visualized using a LI-COR Odyssey scanner and quantified using LI-COR Image Studio v. 5.0.21 software (LI-COR Biosciences). GAPDH or a revert 700 Total Protein Stain (Li-Cor) were used as loading controls.</p>
</sec>
<sec id="s2-8">
<title>Data analysis</title>
<p>Data were presented as the mean &#xb1; SEM. Statistical comparisons used either a t-test (Graphpad <ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/quickcalcs/ttest1/">https://www.graphpad.com/quickcalcs/ttest1/</ext-link>) or a one-way ANOVA plus the <italic>post hoc</italic> Tukey HSD test (<ext-link ext-link-type="uri" xlink:href="https://astatsa.com/OneWay_Anova_with_TukeyHSD/">https://astatsa.com/OneWay_Anova_with_TukeyHSD/</ext-link>). An on-line statistical calculator was used to determine the significance of the slopes in the Pearson coefficient plots (<ext-link ext-link-type="uri" xlink:href="http://www.socscistatistics.com/pvalues/pearsondistribution.aspx">www.socscistatistics.com/pvalues/pearsondistribution.aspx</ext-link>). A <italic>p</italic>-value &#x3c; 0.05 was considered statistically significant. The specific tests used are described within each figure legend. Fold changes in gene expression were performed according to the &#x394;&#x394;Ct method. The RT-qPCR data was normalized using either gene succinate dehydrogenase complex subunit A (SDHA), or hypoxanthine phosphoribosyl transferase 1 (HPRT1).</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<p>Previous studies have shown that TM&#xa0;cells isolated from older donor eyes (&#x3e;70&#xa0;years of age) that express lower levels of the &#x3b1;5&#x3b2;1 integrin (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>) exhibited higher levels of &#x3b1;SMA and formed stress fibers containing &#x3b1;SMA. Western blot analysis and immunofluorescence microscopy confirmed these earlier studies. <xref ref-type="fig" rid="F1">Figures 1A,B</xref> show that three&#xa0;TM&#xa0;cell strains from older donor eyes (74, 75 and 77 years old) expressed significantly higher protein levels of &#x3b1;SMA compared to three TM cell strains isolated from young donor eyes (25, 27 and 27 years old). Older TM cells also assembled more robust &#x3b1;SMA positive stress fibers. <xref ref-type="fig" rid="F1">Figure 1C</xref> shows that TM&#xa0;cells isolated from a 17-year old normal (N17) donor eye did not show any &#x3b1;SMA positive stress fibers. In contrast, TM&#xa0;cells from a 74-year old normal (N74) donor eye contained &#x3b1;SMA positive stress fibers supporting the idea that &#x3b1;SMA is upregulated in older individuals. Interestingly, correlation coefficient analysis of the mRNA levels for &#x3b1;SMA did not show an age-related increase, since the Pearson&#x2019;s coefficient was 0.18 (<xref ref-type="fig" rid="F1">Figure 1D</xref>). This suggests that age was not the predominant driving factor in the upregulation of &#x3b1;SMA mRNA levels. Since the increase was most noticeable in cells that expressed lower levels of &#x3b1;5&#x3b2;1 integrin (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>), we then compared fold changes in mRNA levels for &#x3b1;SMA with fold changes in the mRNA for the &#x3b1;5 integrin subunit (<xref ref-type="fig" rid="F1">Figure 1E</xref>). The correlation coefficient plot had a Pearson&#x2019;s coefficient of <italic>r</italic> &#x3d; &#x2212;0.58 suggesting that there was an inverse relationship between mRNA levels for &#x3b1;SMA and &#x3b1;5 integrin. Thus, the levels of mRNA for &#x3b1;SMA increased as the levels of mRNA for the &#x3b1;5 integrin subunit decreased. This correlation was specific for the &#x3b1;5 integrin subunit since the mRNA for the &#x3b2;3 integrin did not show a significant correlation with mRNA levels for &#x3b1;SMA (compare <xref ref-type="fig" rid="F1">Figure 1E</xref> and <xref ref-type="fig" rid="F1">Figure 1F</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Young TM cells express lower &#x3b1;SMA levels than old TM cells. <bold>(A)</bold> Lysates were harvested from three TM cell strains (N25, N27, N27-2) derived from young donor eyes (ages 25 and 27) and three cell strains (N74, N75, N77) derived from old donor eyes (ages 74, 75, 77) 1&#xa0;week after reaching confluency. Protein lysates from each culture (20&#xa0;&#xb5;g) were run on a 10% SDS-PAGE gel for Western blot analysis and probed with a rabbit anti-&#x3b1;SMA antibody. An anti-GAPDH antibody was used as a loading control. The blot is representative of experiments done in triplicate using biological replicates. <bold>(B)</bold> Densitometry was performed and &#x3b1;SMA levels were normalized to GAPDH levels. &#x3b1;SMA levels in young cells were significantly different from old cells, &#x2a;<italic>p</italic> &#x3c; 0.001. <bold>(C)</bold> Immunofluorescence micrographs of young (N17) and old TM (N74) cells obtained from a 17 and 74- year-old donor eyes plated onto 5&#xa0;&#xb5;g/mL fibronectin and labeled for &#x3b1;SMA. Only the N74 cells showed robust &#x3b1;SMA positive stress fibers. Scale bar &#x3d; 20&#xa0;&#xb5;m. <bold>(D)</bold> Scatter plot comparing levels of &#x3b1;SMA mRNA relative to age. Although levels of &#x3b1;SMA mRNA appear to increase with age, this increase did not show a significant correlation with age. <italic>N</italic> &#x3d; 21 cell strains, ages 17&#x2013;77. <bold>(E,F)</bold> Scatter plots comparing &#x3b1;SMA mRNA levels relative to fold change in &#x3b1;5 and &#x3b2;3 integrin mRNA levels. Fold changes of &#x3b1;SMA mRNA levels showed an inverse correlation to fold changes in &#x3b1;5 integrin mRNA and decreased as &#x3b1;5 integrin mRNA levels increased. The correlation was statistically significant (<italic>p</italic> &#x3c; 0.05) using a t-test. &#x3b1;SMA and &#x3b2;3 integrin mRNA did not show a correlation as &#x3b2;3 integrin mRNA increased. <italic>N</italic> &#x3d; 21 cell strains, ages 17&#x2013;77 (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>). <italic>r</italic> &#x3d; Pearson&#x2019;s coefficient.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g001.tif">
<alt-text content-type="machine-generated">Panel A shows a Western blot comparing &#x3B1;SMA and GAPDH protein levels in young and old cells. Panel B is a bar graph indicating higher &#x3B1;SMA protein average densitometry in old cells. Panel C contains images of N17 and N74 cells stained to show structural differences in &#x3B1;SMA labeling. Panel D is a scatter plot showing a slight positive correlation between age and &#x3B1;SMA mRNA fold change. Panel E depicts a negative correlation between &#x3B1;SMA mRNA and &#x3B1;5 integrin mRNA fold changes. Panel F shows a weak positive correlation between &#x3B1;SMA mRNA and &#x3B2;3 integrin mRNA fold changes.</alt-text>
</graphic>
</fig>
<p>To see if elevated levels of &#x3b1;SMA correlated with TM&#xa0;cells lacking or expressing low levels of &#x3b1;5 integrin expression <italic>in vivo</italic>, human anterior segments from young and old donor eyes were labeled for &#x3b1;SMA (<xref ref-type="fig" rid="F2">Figure 2</xref>) and the &#x3b1;5 integrin subunit (<xref ref-type="fig" rid="F3">Figure 3</xref>). As shown in <xref ref-type="fig" rid="F2">Figures 2B,E,H</xref>, TM&#xa0;cells in tissues from 14, 38, and 73-year-old individuals showed weak &#x3b1;SMA labeling in the JCT region of the TM adjacent to SC in the anterior chamber (AC) compared to TM&#xa0;cells in the JCT of the anterior segment from a 74-year-old individual (<xref ref-type="fig" rid="F2">Figure 2K</xref>). Analysis of the &#x3b1;5 integrin levels in those same tissues showed that, unlike the tissues from the 14, 38- and 73-year-old individuals, the TM and SC from the 74-year-old which contained high levels of &#x3b1;SMA (<xref ref-type="fig" rid="F2">Figure 2K</xref>) had very low levels of &#x3b1;5&#x3b2;1 integrin (<xref ref-type="fig" rid="F3">Figure 3G</xref>). This suggests that there may be an inverse correlation between &#x3b1;SMA and &#x3b1;5 integrin expression <italic>in vivo</italic>.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Immunolabeling for &#x3b1;SMA in human anterior segments from young and old eyes. <bold>(A,D,G,J)</bold> H&#x26;E staining of the TM/SC pathways of donors of 14, 38, 73, and 74&#xa0;years of age, respectively. <bold>(B)</bold> &#x3b1;SMA labeling was essentially absent from the 14-year-old donor tissue. <bold>(E,H)</bold> Weak &#x3b1;SMA labeling (solid arrows) was observed in the trabecular beams, JCT and SC of the 38 and 73- year-old donor tissue, although strong labeling was observed in portions of the SC inner wall in the 73-year-old donor tissue. <bold>(K)</bold> Very strong &#x3b1;SMA labeling (solid arrows) was observed throughout much of the TM/SC pathway of the 74-year-old donor tissue including the JCT and SC. This includes the SC outer wall (arrowheads). <bold>(C,F,I,L)</bold> No labeling was observed in sections incubated with a control antibody against &#x3b2;-galactosidase. Nuclei are identified in sections labeled for &#x3b1;SMA or &#x3b2;-galactosidase using Hoechst 33342. AC, anterior chamber; TM, trabecular meshwork; SC, Schlemm Canal which is outlined with a dashed line and JCT, juxtacanalicular tissue. Asterisks in <bold>(B,E,H,K)</bold> indicate enlarged areas shown in the insets. Scale bar &#x3d; 50&#xa0;&#xb5;m in <bold>(A,B)</bold>.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g002.tif">
<alt-text content-type="machine-generated">Histological and immunofluorescence images of eye tissues showing differences in &#x3b1;SMA labeling  with age. Panels A, D, G, J are histological sections showing location of  anterior chamber (AC),  trabecular meshwork (TM), and Schlemm&#x27;s canal (SC) for tissues from donor eyes ages 14, 38, 73, and 74 years old, respectively. Panels B, E, H, K show increase in  &#x3b1;SMA  labeling in juxtacanalicular tissue (JCT) in sections as the age of donor tissue increases. Enhanced views of  JCT shown in inserts. Panels C, F, I, L show no labeling in corresponding tissue sections labeled with  control antibody for each age group. TM structure is outlined in all labeled sections. Cell nuclei shown in blue.</alt-text>
</graphic>
</fig>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>Immunolabeling for &#x3b1;5 integrin in human anterior segments from young and old eyes. Localization of &#x3b1;5 integrin in the trabecular meshworks of 14, 38, 73. and 74-year-old donor tissue used in <xref ref-type="fig" rid="F2">Figure 2</xref>. <bold>(A,C)</bold> Integrin labeling intensity was relatively strong in the 14-year-old donor tissue and moderate in the 38-year-old donor tissue, respectively. &#x3b1;5 integrin was localized in the cells found on the trabecular beams and in the JCT of the TM and in the SC endothelial cells of both tissue samples. <bold>(E)</bold> Weak to moderate &#x3b1;5 integrin labeling intensity was also observed in the TM/SC in the 73- year-old tissue. <bold>(G)</bold> Weak &#x3b1;5 integrin labeling was observed in the TM/SC from the 74-year-old donor. <bold>(B,D,F,H)</bold> No labeling was observed in sections from the same donor tissues incubated with a control antibody against &#x3b2;-galactosidase. Arrows &#x3d; &#x3b1;5 integrin-positive cells. TM, trabecular meshwork; SC, Schlemm Canal which is outlined with a dashed line; JCT, juxtacanalicular tissue. Scale bar in panel A &#x3d; 20&#xa0;&#xb5;m.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g003.tif">
<alt-text content-type="machine-generated">Eight fluorescent microscopy images showing trabecular meshwork (TM) and juxtacanalicular connective tissue (JCT) at different ages: 14, 38, 73, and 74 years old. Panels A, C, E, and G display orange-brown staining with highlighted TM and JCT areas marked by arrows. Panels B, D, F, and H highlight blue-stained features, indicating cellular components. Each pair of panels represents a specific age, providing a comparative view of tissue structures with varying orange and blue contrast over time. Dashed lines demarcate tissue boundaries.</alt-text>
</graphic>
</fig>
<p>Since integrins have been shown to control actomyosin stress fiber formation (<xref ref-type="bibr" rid="B4">Burridge and Chrzanowska-Wodnicka, 1996</xref>; <xref ref-type="bibr" rid="B62">Schoenwaelder and Burridge, 1999</xref>), we wanted to determine whether &#x3b1;SMA expression was dependent on &#x3b1;5&#x3b2;1 integrin expression. To test this, we used &#x3b1;5 shRNA lentiviral particles to knockdown expression of &#x3b1;5&#x3b2;1 integrin in cells from two young normal donor eyes ages 25 (N25) and 35 (N35) to see if this would lead to an increase in &#x3b1;SMA levels. <xref ref-type="fig" rid="F4">Figure 4A</xref> shows that transducing cells with 100 or 150 MOI of &#x3b1;5 integrin shRNA lentiviral particles resulted in a statistically significant (<italic>p</italic> &#x3c; 0.001) 60% knockdown in &#x3b1;5 integrin mRNA compared to control cells not transduced (0; Con UT) with the &#x3b1;5 shRNA lentiviral particles. To further demonstrate specificity of the knockdown, we transduced cells with a non-targeting shRNA lentiviral vector (Con NT). As shown in <xref ref-type="fig" rid="F4">Figure 4B</xref>, non-targeting shRNA lentiviral particles had no effect on the levels of &#x3b1;5 integrin mRNA compared to untransduced control cells (Con UT). Western blot analysis of the cells transduced with either 100 or 150 MOI of the &#x3b1;5 integrin shRNA lentiviral particles verified the specificity of the knockdown and showed that the knockdown resulted in a statistically significant (<italic>p</italic> &#x3c; 0.001) 40% decrease in the protein levels of &#x3b1;5 integrin (<xref ref-type="fig" rid="F4">Figures 4C,D</xref>). To further demonstrate specificity of the knockdown, we looked to see if the knockdown of &#x3b1;5 integrin affected the level of the &#x3b2;3 integrin. As shown in <xref ref-type="fig" rid="F4">Figures 4E,F</xref>, knockdown of &#x3b1;5 integrin mRNA and protein levels did not result in a significant change in either &#x3b2;3 integrin mRNA or its protein levels, even when higher MOIs of the &#x3b1;5 integrin shRNA lentiviral particles were used suggesting that the &#x3b1;5 shRNA was specific for &#x3b1;5 integrin subunit.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Knockdown of &#x3b1;5 integrin subunit in young TM cells triggers an increase in &#x3b1;SMA expression. <bold>(A)</bold> Cells isolated from 25 and 35&#x2010;year&#x2010;old donor eyes were transduced with increasing MOIs of &#x3b1;5 integrin shRNA lentiviral particles (MOI 50, 100, 150). By RT-qPCR, there was a significant 60% reduction in &#x3b1;5 integrin mRNA at the 100 and 150 MOIs compared to cells not transduced (0). <bold>(B)</bold> TM cells transduced with non-targeting control lentiviral particles (Con-NT) showed no statistical difference in the mRNA levels for the &#x3b1;5 integrin compared to untransduced control cells (Con-UT). In contrast, cells transduced with &#x3b1;5 integrin shRNA lentiviral particles (MOI 100) showed a statistically significant 50% decrease in the mRNA levels for the &#x3b1;5 integrin. <bold>(C)</bold> A significant reduction in protein levels was also observed at all MOIs used. The &#x3b1;5 integrin protein levels were normalized to GAPDH which was used as a loading control. <bold>(D)</bold> Representative SDS-PAGE of &#x3b1;5 integrin levels obtained from N35 cells transduced at a MOI of 100 and untransduced control cells. Experiments were done in triplicates using two biological replicates (N25 and N35 cells). <bold>(E,F)</bold> Levels of mRNA and protein for the &#x3b2;3 integrin were unaffected by &#x3b1;5 integrin knockdown at any MOI used. <bold>(G)</bold> Densitometry of western blots of cell lysates from N25 and N35 cells showed &#x3b1;SMA protein levels were elevated in cells transduced at a MOI of 100. &#x3b1;SMA levels were normalized to GAPDH levels. <bold>(H)</bold> Representative Western blot of &#x3b1;SMA levels in transduced and non-transduced N35 cells. Blots were down in triplicate using biological replicates of each cell strain and repeated twice. <bold>(I)</bold> Representative images of immunofluorescence labeling of untransduced and transduced N35 TM cells for &#x3b1;SMA showed that the level of &#x3b1;SMA intensity varied between the cells but was increased in &#x3b1;5 integrin shRNA transduced cells. The variation in cell spreading could be due to the fact that cells were not synchronized prior to the start of the spreading assay. <bold>(J)</bold> Relative mean fluorescence intensity (RFI) of total &#x3b1;SMA labeling in non-transduced and transduced N25 and N35 cells plated on collagen. Transduced cells show a statistically significant increase in &#x3b1;SMA labeling compared to non-transduced cells. <italic>N</italic> &#x3d; 40 cells per treatment group. &#x2a;<italic>p</italic> &#x3c;0.001, &#x2a;&#x2a;<italic>p</italic> &#x3c; 0.003 Experiments were done in triplicates. Scale bar &#x3d; 20&#xa0;&#xb5;m. Data for RT-qPCR, densitometry and RFI studies were pooled data from N25 and N35 cells.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g004.tif">
<alt-text content-type="machine-generated">Graphs and images illustrate the effects of using &#x3b1;5 integrin shRNA particles to knockdown &#x3b1;5 integrin mRNA and protein levels. Panels A and B, bar graphs showing decreased &#x3b1;5 integrin mRNA levels with increasing shRNA compared to controls. Panel C, bar graph showing  densitometry of Western blots. indicate a reduction in &#x3b1;5 integrin protein levels in transduced cells compared to control cells. GAPDH was used as a loading control. Panel D, representative Western blot of &#x3b1;5 integrin and GAPDH levels. Panels E and F are bar graphs showing stable &#x3b2;3 integrin mRNA and protein levels across all shRNA doses used. Panel G, bar graph showing &#x3b1;SMA protein levels are reduced in cells transduced with &#x3b1;5 integrin shRNA particles. Panel H, representative Western blot of &#x3b1;SMA and GAPDH levels. Panel I, Immunofluorescence images of &#x3b1;SMA labeling in control vs shRNA transduced cells.</alt-text>
</graphic>
</fig>
<p>Knocking down expression of the &#x3b1;5 integrin subunit, however, did result in an increase in the expression of &#x3b1;SMA protein levels in cells transduced with the &#x3b1;5 integrin shRNA lentivirus (<xref ref-type="fig" rid="F4">Figures 4G&#x2013;J</xref>). Western blot analysis (<xref ref-type="fig" rid="F4">Figures 4G,H</xref>) showed that there was a modest increase in &#x3b1;SMA in the &#x3b1;5 integrin shRNA transduced cells compared to control untransduced cells when the levels were normalized to the GAPDH control, although this increase was not statistically significant. This increase, however, was supported by immunofluorescence microscopy studies that showed a statistically significant increase in the intensity of &#x3b1;SMA expression in transduced cells (<xref ref-type="fig" rid="F4">Figures 4I,J</xref>) at both a MOI of 100 (<italic>p</italic> &#x3c; 0.003) and 150 (<italic>p</italic> &#x3c; 0.001) compared to the non-transduced cells. <xref ref-type="fig" rid="F4">Figure 4I</xref> shows representative images of &#x3b1;SMA labeling in non-transduced and transduced N35 cells.</p>
<p>As expected from our previous studies (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>), the increase in the intensity of &#x3b1;SMA expression correlated with increased levels of activated &#x3b1;v&#x3b2;3 integrin in focal adhesions. Using the same cells shown in <xref ref-type="fig" rid="F4">Figure 4</xref>, <xref ref-type="fig" rid="F5">Figures 5A,B</xref> show that knockdown of the &#x3b1;5 integrin subunit did not affect the percentage of N25 and N35 cells expressing total &#x3b1;v&#x3b2;3 integrin in focal adhesions plated on collagen. However, the knockdown of &#x3b1;5 integrin subunit did cause a statistically significant (<italic>p</italic> &#x3c; 0.001) increase in the percentage of N25 and N35 cells containing active &#x3b1;v&#x3b2;3 integrins in focal adhesions (<xref ref-type="fig" rid="F5">Figures 5C,D</xref>). This increase in activated levels of &#x3b1;v&#x3b2;3 integrin corresponded to an increase in &#x3b1;SMA intensity in the N25 and N35 cells by immunofluorescence microscopy (<xref ref-type="fig" rid="F4">Figure 4J</xref>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Knockdown of a5 integrin subunit triggers an increase in &#x3b1;v&#x3b2;3 integrin activity in focal adhesions in young TM cells on collagen. <bold>(A)</bold> Cells labeled with Alexa 488 conjugated phalloidin (green) to localize actin filaments and with mAb [BV3] (red) show both transduced and untransduced TM cells plated on collagen contained numerous focal adhesions (white arrows) containing &#x3b1;v&#x3b2;3 integrin. <bold>(B)</bold> Quantitation of percentage of untransduced and transduced cells containing three or more focal adhesions with &#x3b1;v&#x3b2;3 integrin. No statistical difference in the percentage of cells that contained total &#x3b1;v&#x3b2;3 integrin in focal adhesions was detected. <bold>(C)</bold> Cells were labeled for active &#x3b1;v&#x3b2;3 integrin (mAb LIBS2, red) in focal adhesions and actin stress filaments (Alexa 488-phalloidin, green) in transduced and untransduced N25 and N35 cells plated on collagen. More transduced TM cells contained focal adhesions (white arrows) with active &#x3b1;v&#x3b2;3 integrin than untransduced cells. <bold>(D)</bold> Quantitation of the percentage of untransduced and transduced N25 and N35 cells containing three or more focal adhesions with active &#x3b1;v&#x3b2;3 integrin. Transduced TM cells showed a statistically significant (<italic>p</italic> &#x3c; 0.001) difference in the percentage of cells that contained active &#x3b1;v&#x3b2;3 integrin in focal adhesions. Scale bar &#x3d; 20&#xa0;&#xb5;m. Experiments were done in triplicates using two biological replicates. <italic>N</italic> &#x3d; 40 cells.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g005.tif">
<alt-text content-type="machine-generated">Levels of &#x3b1;v&#x3b2;3 integrin expression in focal adhesions in young trabecular meshwork cells transduced with &#x3b1;5 shRNA and plated on collagen. Panel A, immunofluorescent  images show total &#x3b1;v&#x3b2;3 integrin levels in focal adhesions. Panel B,  box plots comparing percentage of &#x3b1;v&#x3b2;3 integrin&#x2010;positive cells in control and &#x3b1;5 shRNA transduced cells. Plots indicate little differences. Panel C, immunofluorescent  images show active &#x3b1;v&#x3b2;3 integrin levels in focal adhesions. Panel D, box plots comparing percentage of cells with active &#x3b1;v&#x3b2;3 integrin  in focal adhesions.  Plots indicate higher levels of active &#x3b1;v&#x3b2;3 integrin in focal adhesions. in transduced cells. Cell samples were from 25 and 35 donor eye tissues. Arrows in panels A and C point to areas of interest.</alt-text>
</graphic>
</fig>
<p>We then repeated the study to see if we saw similar results when we plated the &#x3b1;5 integrin knockout TM cells on fibronectin to determine if the substrate cells were plated on could affect the expression of &#x3b1;SMA. As shown in <xref ref-type="fig" rid="F6">Figures 6A,C</xref>, there was no significant difference in total &#x3b1;v&#x3b2;3 integrin-positive focal adhesions between transduced and non-transduced N25 and N35 cells plated on fibronectin. In contrast, the knockdown of &#x3b1;5 integrin subunit in both N25 and N35 cells resulted in a statistically significant increase (<italic>p</italic> &#x3c; 0.001) in the percentage of cells containing activated &#x3b1;v&#x3b2;3 integrin in focal adhesions (<xref ref-type="fig" rid="F6">Figures 6B,D</xref>). The increase in activated &#x3b1;v&#x3b2;3 integrin correlated with an increase in the intensity of &#x3b1;SMA labeling in transduced cells compared to non-transduced cells (<xref ref-type="fig" rid="F6">Figures 6E,F</xref>). This suggests that the increase in activated &#x3b1;v&#x3b2;3 integrin and &#x3b1;SMA levels were not dependent on the substrate. Interestingly, whether the cells were plated on collagen or fibronectin, we rarely saw well-formed robust &#x3b1;SMA containing stress fibers in these transduced young cells like the ones we saw in older TM cells (compare <xref ref-type="fig" rid="F1">Figure 1C</xref> to <xref ref-type="fig" rid="F4">Figure 4I</xref>). This suggests that although activated levels of &#x3b2;3 integrin are associated with the expression of &#x3b1;SMA, some other factor(s) such as the expression of a specific tropomyosin isoform may be needed for the robust assembly of &#x3b1;SMA into the stress fibers seen in older cells (<xref ref-type="bibr" rid="B59">Prunotto et al., 2015</xref>).</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>Knockdown of a5 integrin subunit triggers an increase in &#x3b1;v&#x3b2;3 integrin activity in focal adhesions in young TM cells on fibronectin. <bold>(A)</bold> Immunolabeling for total &#x3b1;v&#x3b2;3 integrin (mAb [BV3], red) in focal adhesions and actin filaments with Alexa 488-phalloidin (green) in transduced and untransduced N25 and N35 cells plated on fibronectin. Both transduced and untransduced TM cells contained numerous focal adhesions (white arrows) containing &#x3b1;v&#x3b2;3 integrin. <bold>(B)</bold> Immunolabeling for active &#x3b1;v&#x3b2;3 integrin (mAb LIBS2, red) in focal adhesions and actin filaments (Alexa 488-phalloidin, green) in transduced and untransduced N25 and N35 cells plated on fibronectin. More untransduced TM cells contained focal adhesions (white arrows) containing active &#x3b1;v&#x3b2;3 integrin. <bold>(C)</bold> Quantitation of percentage of untransduced and transduced N25 and N35 cells containing three or more focal adhesions with &#x3b1;v&#x3b2;3 integrin. No statistical difference in the percentage of cells that contained total &#x3b1;v&#x3b2;3 integrin in focal adhesions was detected. Experiments were done in duplicates using two biological replicates. <italic>N</italic> &#x3d; 40 cells. <bold>(D)</bold> Quantitation of the percentage of untransduced and transduced cells containing three or more focal adhesions with active &#x3b1;v&#x3b2;3 integrin. Transduced TM cells showed a statistically significant increase in the percentage of cells that contained active &#x3b1;v&#x3b2;3 integrin in focal adhesions. <italic>N</italic> &#x3d; 40 cells. <bold>(E)</bold> Representative immunofluorescence images of untransduced and transduced N25 and N35 TM cells plated on fibronectin and labeled for &#x3b1;SMA. Images show that the &#x3b1;SMA intensity appears to be greater in transduced cells. Scale bar &#x3d; 20&#xa0;&#xb5;m. <bold>(F)</bold> Relative mean fluorescent intensity (RFI) of total &#x3b1;SMA labeling in untransduced and transduced N25 and N35 cells. Transduced cells show a statistically significant increase in &#x3b1;SMA labeling intensity compared to non-transduced cells. <italic>N</italic> &#x3d; 40 cells.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g006.tif">
<alt-text content-type="machine-generated">Level of &#x3b1;v&#x3b2;3 integrin expression in focal adhesions in young trabecular meshwork cells transduced with &#x3b1;5 shRNA and plated on fibronectin. Panels A and B show total and active &#x3b1;v&#x3b2;3 integrin levels, respectively in focal adhesions. Panel C, box plots comparing percentage of &#x3b1;v&#x3b2;3 integrin-positive cells in control and &#x3b1;5 shRNA transduced cells. Plots indicate little differences. Panel D is a box plot comparing percentage of active &#x3b1;v&#x3b2;3 integrin-positive cells in control and &#x3b1;5 shRNA transduced cells. Plots indicate higher levels in transduced cells. Panel E, Immunofluorescent images showing increased expression of &#x3b1;SMA in transduced cells. Panel F, box plots showing higher levels of &#x3b1;SMA intensity in &#x3b1;5 shRNA transduced cells. Cell samples were from 25 and 35 donor eye tissues. Arrows in panels A and B point to areas of interest.</alt-text>
</graphic>
</fig>
<p>To see if &#x3b2;3 integrin was involved in the expression of &#x3b1;SMA, we then used shRNA lentiviral particles to knockdown expression of the &#x3b2;3 integrin subunit in TM cells isolated from a normal donor eye age 77 (N77). These older TM&#xa0;cells, which form &#x3b1;SMA positive stress fibers, had previously been shown to contain high levels of activated &#x3b1;v&#x3b2;3 integrin and expressed very low levels of &#x3b1;5&#x3b2;1 integrin (<xref ref-type="bibr" rid="B35">Johns et al., 2025</xref>). As shown in <xref ref-type="fig" rid="F7">Figure 7A</xref>, a MOI of 100 resulted in a knockdown of the &#x3b2;3 integrin mRNA by 40% (<italic>p</italic> &#x3c; 0.008) compared to untransduced control cells. In contrast, transduction with non-targeting lentiviral particles had no effect on &#x3b2;3 integrin mRNA levels (<xref ref-type="fig" rid="F7">Figure 7B</xref>). As shown in <xref ref-type="fig" rid="F7">Figures 7C,D</xref>, knockdown of the &#x3b2;3 integrin mRNA resulted in a 60% decrease (<italic>p</italic> &#x3c; 0.006) in protein levels. When we looked at the levels of &#x3b1;SMA in the &#x3b2;3 integrin knockdown cells compared to untransduced cells, we saw that the levels of <italic>&#x3b1;SMA</italic> mRNA and protein levels were significantly reduced by 40% (<italic>p</italic> &#x3c; 0.002) and 60% (<italic>p</italic> &#x3c; 0.00006), respectively (<xref ref-type="fig" rid="F7">Figures 7E,G,H</xref>). As expected, transduction with the non-targeting lentiviral vector had no statistical effect on <italic>&#x3b1;SMA</italic> mRNA levels (<xref ref-type="fig" rid="F7">Figure 7F</xref>). By immunofluorescence microscopy, we saw a statistically significant (<italic>p</italic> &#x3c; 0.00006) decrease in &#x3b1;SMA in the cytoplasm of cells regardless of whether they were plated on collagen or fibronectin coated coverslips (<xref ref-type="fig" rid="F7">Figures 7I&#x2013;K</xref>). This suggests that expression of &#x3b1;v&#x3b2;3 integrin affects the mRNA and protein levels for &#x3b1;SMA in TM&#xa0;cells and hence, it may be involved in the transition of TM&#xa0;cells into a mesenchymal phenotype since &#x3b1;SMA is considered an early biomarker for this transition.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Knockdown of &#x3b2;3 integrin subunit in TM cells from a 77 year-old triggers a decrease in &#x3b1;SMA levels. <bold>(A)</bold> N<bold>77</bold> TM cells were transduced with &#x3b2;3 shRNA lentiviral particles (MOI 100). By RT-qPCR, there was a significant 40% reduction in &#x3b2;3 integrin mRNA compared to untransduced cells (&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.008). <bold>(B)</bold> N77 TM cells transduced with a non-targeting lentiviral vector showed no statistically significant difference in &#x3b2;3 integrin mRNA levels compared to untransduced cells. <bold>(C)</bold> Densitometry of Western blot analyses of &#x3b2;3 integrin protein levels also showed a statistically significant 60% decrease (&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.006) in &#x3b2;3 integrin protein levels compared to untransduced cells. <bold>(D)</bold> Representative western blots of cell lysates from transduced and untransduced cells. GAPDH was used as a loading control. <bold>(E)</bold> RT-qPCR showed &#x3b1;SMA mRNA levels were significantly reduced (&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.002) by 40% in transduced cells. <bold>(F)</bold> TM cells transduced with non-targeting lentivirus particles showed no statistically significant difference in &#x3b1;SMA mRNA levels compared to untransduced cells. <bold>(G)</bold> Densitometry of western blots showed that protein levels were also significantly reduced (&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0006) in cells transduced at a MOI of 100 compared to untransduced cells. &#x3b1;SMA levels were normalized to GAPDH levels. <bold>(H)</bold> Representative Western blot of &#x3b1;SMA levels in transduced and untransduced cells. <bold>(I)</bold> Immunolabeling studies showed that transduced cells plated on collagen or fibronectin had no &#x3b1;SMA-positive stress fibers. In contrast, untransduced cells contained &#x3b1;SMA-positive stress fibers. <bold>(J,K)</bold> Relative fluorescence intensity of &#x3b1;SMA labeling in untransduced and transduced cells plated on either collagen <bold>(J)</bold> or fibronectin <bold>(K)</bold>. Transduced cells show a statistically significant decrease (&#x2a;&#x2a;&#x2a;<italic>p</italic> &#x3c; 0.0006) in &#x3b1;SMA labeling intensity. Scale bar &#x3d; 20&#xa0;&#xb5;m. All experiments were done in triplicates using technical replicates from independent experiments.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g007.tif">
<alt-text content-type="machine-generated">Bar graphs and Western blots depict the impact of &#x3B2;3 integrin and &#x3B1;SMA expression after shRNA treatment. Panels A, E, and G show reduced mRNA and protein levels with &#x3B2;3 shRNA treatment. Panel D and H include corresponding blots for &#x3B2;3 and &#x3B1;SMA with GAPDH control. Images in panel I illustrate cell morphology differences on collagen and FN substrates, with arrows pointing to cells. Box plots J and K display decreased &#x3B1;SMA intensity with &#x3B2;3 shRNA treatment. Statistical significance is noted with asterisks.</alt-text>
</graphic>
</fig>
<p>We then examined whether other biomarkers involved in EndMT might be affected by changes in the expression and/or activity of &#x3b1;5&#x3b2;1 and &#x3b1;v&#x3b2;3 integrins in TM cells. Other biomarkers for a mesenchymal phenotype in EndMT that we investigated were SNAI1, SNAI2, Vimentin, TWIST1, and TWIST2 (<xref ref-type="bibr" rid="B45">Lamouille et al., 2014</xref>; <xref ref-type="bibr" rid="B49">Lovisa et al., 2020</xref>). SNAIs and TWISTs are transcription factors whose expression occurs early at the onset of EndMT and play a central role in driving EndMT, whereas vimentin is an intermediate filament that is upregulated in mesenchymal cells (<xref ref-type="bibr" rid="B34">Islam et al., 2021</xref>). As shown in <xref ref-type="fig" rid="F8">Figures 8A&#x2013;C</xref>, we used three populations of TM cells for the study. The first population of TM cells were obtained from donor eyes (ages 17&#x2013;36&#xa0;years old). Flow cytometry studies showed that the majority of the young cells expressed &#x3b1;5&#x3b2;1 (92%) and &#x3b1;v&#x3b2;3 (94%) integrins on their cell surface (<xref ref-type="fig" rid="F8">Figures 8A,B</xref>). However, as shown in <xref ref-type="fig" rid="F8">Figure 8C</xref>, very few of these cells (only 19%) expressed the activated form of &#x3b1;v&#x3b2;3 integrin on their cell surface. We called these cells young &#x3b1;5&#x2b; cells. The second group of TM cells which we called old &#x3b1;5 integrin&#x2b; were from older individuals (ages 55&#x2013;75). Like the young &#x3b1;5&#x2b; cells, a large percentage of these cells expressed &#x3b1;5&#x3b2;1 (94%) and &#x3b1;v&#x3b2;3 (71%) integrins on their cell surface and only a few expressed the active form of &#x3b1;v&#x3b2;3 integrin (13%). The third population of the TM&#xa0;cells that we called old &#x3b1;5- were also from older normal donor eyes (ages 74 and 77). However, their integrin profile differed significantly (<italic>p</italic> &#x3c; 0.02) from the other cell strains. Less than half the population expressed the &#x3b1;5&#x3b2;1 integrin (45%) on their cell surface and nearly all of the cells (93%) expressed &#x3b1;v&#x3b2;3 integrin. In addition, a greater percentage of the old &#x3b1;5-cells (36% compared to 19% or 13%) expressed the activated form of &#x3b1;v&#x3b2;3 integrin on their cell surface.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>Activity of <italic>&#x3b1;v&#x3b2;3</italic> integrin affects the expression of <italic>VIM</italic>, <italic>SNAI2</italic>, and <italic>TWIST1</italic> mRNA levels. <bold>(A)</bold> Flow cytometry showed that TM cells (Old &#x3b1;5-) derived from 74 to 77-year-old donor eyes expressed lower levels of &#x3b1;5 integrin compared to TM cells derived from young (young &#x3b1;5&#x2b;) and other old donor eyes (old &#x3b1;5&#x2b;). The designation &#x3b1;5&#x2b; refers to the fact that a large percentage of cells express the &#x3b1;5 integrin subunit while &#x3b1;5- refers to the fact that most of these cells do not express the &#x3b1;5 integrin subunit. <bold>(B)</bold> Despite differences in the levels of the &#x3b1;5 integrin subunit, all three populations of cells expressed similar levels of &#x3b2;3 integrin. <bold>(C)</bold> More old a5- TM cells (N74 and N77) expressed active &#x3b1;v&#x3b2;3 integrin on the cell surface compared to young and old TM cells expressing &#x3b1;5&#x3b2;1 integrins; &#x2a;<italic>p</italic> &#x3c; 0.02. <italic>N</italic> &#x3d; 10,000 cells per condition. <italic>N</italic> &#x3d; 7 young &#x3b1;5&#x2b; biological replicates (ages 17&#x2013;36), <italic>N</italic> &#x3d; 5 old &#x3b1;5&#x2b; biological replicates expressing &#x3b1;5&#x3b2;1 integrin (ages 55&#x2013;75). <italic>N</italic> &#x3d; 2 old &#x3b1;5- biological replicates (ages 74&#x2013;77). Cells were labeled with P1D6 (&#x3b1;5&#x3b2;1 integrin), LM609 (total &#x3b1;v&#x3b2;3 integrin), or LIBS2 (active &#x3b1;v&#x3b2;3 integrin) mAbs. <bold>(D,E)</bold> RT-qPCR showed that Old &#x3b1;5- TM cells expressed significantly higher levels (<italic>p</italic> &#x3c; 0.04) of mRNA for the EndMT markers <italic>VIM</italic> and <italic>SNAI2</italic> compared to cells isolated from young &#x3b1;5&#x2b; donor eyes (N25 and N35).<bold>(F)</bold> <italic>TWIST1</italic> mRNA levels were also higher in the old &#x3b1;5 integrin negative cells but the levels were not statistically significant (<italic>p</italic> &#x3c; 0.08). <bold>(G&#x2013;I)</bold> Knockdown of &#x3b2;3 integrin using shRNA in the old N77 cells (Old &#x3b1;5-) that contained elevated levels of active &#x3b1;v&#x3b2;3 integrin and low levels of &#x3b1;5&#x3b2;1 integrin mRNA had statistically reduced levels of <italic>VIM</italic> (<italic>p</italic> &#x3c; 0.0004) and <italic>TWIST1</italic> (<italic>p</italic> &#x3c; 0.01) mRNA. Levels of <italic>SNAI2</italic> mRNA levels were also reduced, but not statistically (<italic>p</italic> &#x3c; 0.07). All experiments were done in triplicates and repeated twice.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g008.tif">
<alt-text content-type="machine-generated">Panels A&#x2010;C, bar graphs comparing levels of &#x3b1;5, &#x3b2;3, and active &#x3b2;3 integrin in young and old trabecular meshwork cells. When &#x3b1;5 levels are low in old cells, an increase in active &#x3b2;3 levels is seen. Panels D&#x2010;F, bar graphs suggest that old cells expressing low levels of &#x3b1;5, integrin and high levels of active &#x3b2;3 integrin show an increase in mRNA levels for VIM, SNAI2, and TWIST1. Panels G&#x2010;I, bar graphs show that when &#x3b2;3 integrin levels are reduced using &#x3b2;3 integrin shRNA, there is a decrease in VIM, SNAI2, and TWIST1 mRNA levels. Significant changes are marked with asterisks.</alt-text>
</graphic>
</fig>
<p>When we then compared the levels of EndMT biomarkers in the old &#x3b1;5-cells that expressed low levels of the &#x3b1;5 integrin subunit to the &#x3b1;5&#x2b; TM&#xa0;cells. As shown in <xref ref-type="fig" rid="F8">Figures 8D&#x2013;F</xref>, we found that the old &#x3b1;5- cells expressed statistically (<italic>p</italic> &#x3c; 0.04) higher levels of both <italic>VIM</italic> and <italic>SNAI2</italic> mRNA compared to the young &#x3b1;5&#x2b;TM cells. The <italic>TWIST1</italic> mRNA levels also appeared to be higher in these old &#x3b1;5-TM cells, but the increase was not statistically significant (<italic>p</italic> &#x3c; 0.08). Interestingly, the levels of <italic>VIM</italic>, <italic>SNAI2</italic>, and <italic>TWIST1</italic> mRNA also appeared to be higher in the old &#x3b1;5&#x2b;TM cells that express high levels of &#x3b1;5&#x3b2;1 integrin. However, this increase in <italic>VIM</italic>, <italic>SNAI2</italic>, and <italic>TWIST1</italic> mRNA in these old &#x3b1;5&#x2b; positive cells was not statistically significant. <italic>SNAI1</italic> and <italic>TWIST2</italic> mRNA were not detected in any of these cells. Hence, these studies suggest that as &#x3b1;5 integrin levels decrease and the level of activated &#x3b1;v&#x3b2;3 integrin increases, the expression of these mesenchymal markers for EndMT are affected.</p>
<p>Since the knockdown of &#x3b1;v&#x3b2;3 integrin appeared to reverse the effect on &#x3b1;SMA caused by the decrease in &#x3b1;5&#x3b2;1 integrin (<xref ref-type="fig" rid="F7">Figure 7</xref>), we then looked at the mRNA levels for <italic>VIM</italic>, <italic>SNAI2</italic>, and <italic>TWIST1</italic> in the &#x3b2;3 shRNA lentiviral transduced old &#x3b1;5-TM cells as well (<xref ref-type="fig" rid="F8">Figures 8G&#x2013;I</xref>). As was seen for <italic>&#x3b1;SMA</italic> mRNA levels (<xref ref-type="fig" rid="F7">Figure 7E</xref>), we saw a statistically significant decrease in <italic>VIM</italic> (<italic>p</italic> &#x3c; 0.0004) and <italic>TWIST1</italic> (<italic>p</italic> &#x3c; 0.02) mRNA levels in the &#x3b1;v&#x3b2;3 integrin knockdown cells compared to untransduced cells. <italic>SNAI2</italic> mRNA levels were also lower in these knockdown cells, however, the reduction was not statistically significant (<italic>p</italic> &#x3c; 0.08). Together these results suggest that expression of some EndMT biomarkers may be influenced by the expression levels of &#x3b1;5&#x3b2;1 integrins and the activity of &#x3b1;v&#x3b2;3 integrins.</p>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>In this study, we show that changes in integrin expression contribute to the development of a mesenchymal phenotype in TM cells. This process which is commonly known as integrin switching (<xref ref-type="bibr" rid="B52">Madamanchi et al., 2014</xref>) resulted in a decrease in &#x3b1;5 integrin mRNA levels and the subsequent activation of &#x3b1;v&#x3b2;3 integrin. Together these changes contribute to an increase in both &#x3b1;SMA mRNA and proteins levels and the assembly of &#x3b1;SMA into stress fibers, an early marker of EMT. We also saw that the expression of other mesenchymal biomarkers such as vimentin, SNAI2 and TWIST1 were also affected by this switch in integrin expression. Together these studies suggest that the increase in &#x3b1;v&#x3b2;3 integrin activity caused by a decrease in &#x3b1;5&#x3b2;1 integrin expression may be an early step in the development of mesenchymal phenotype in TM cells.</p>
<p>Although changes in integrin expression have been known to play a role in the development of an EMT/EndMT phenotype in multiple tissues (<xref ref-type="bibr" rid="B58">Piera-Velazquez and Jimenez, 2019</xref>; <xref ref-type="bibr" rid="B25">Galliher and Schiemann, 2006</xref>; <xref ref-type="bibr" rid="B54">Parvani et al., 2015</xref>), this is the first study to suggest that the ratio between active &#x3b1;v&#x3b2;3 integrin levels and &#x3b1;5&#x3b2;1 integrin expression may control the expression of early markers of EMT/EndMT. Specifically, we found that when the protein and mRNA levels of &#x3b1;5&#x3b2;1 integrin are low and the levels of active &#x3b1;v&#x3b2;3 integrin are high, we saw an increase in the mRNA levels for EndMT markers <italic>&#x3b1;SMA</italic>, <italic>VIM</italic>, <italic>SNAI2</italic> and <italic>TWIST1</italic>. In contrast, when we lowered the levels of &#x3b2;3 integrin with shRNA in old TM cells, we triggered a decrease in <italic>&#x3b1;SMA</italic>, <italic>VIM</italic>, <italic>SNAI2</italic> and <italic>TWIST1</italic> mRNA expression. Since the expression of these markers defines the beginning of the phenotypic transition to myofibroblasts and the mesenchymal phenotype (<xref ref-type="bibr" rid="B32">Hinz et al., 2012</xref>; <xref ref-type="bibr" rid="B37">Jones and Ehrlich, 2011</xref>), this suggests that the activation levels of &#x3b1;v&#x3b2;3 integrin relative to &#x3b1;5&#x3b2;1 integrin levels is an early event in the mesenchymal transition of a TM cell into a myofibroblast. In addition, since these biomarkers have previously been reported to be upregulated in glaucomatous cells, this suggests that integrin switching may be involved in the development of glaucoma (<xref ref-type="bibr" rid="B75">Yang et al., 2025</xref>).</p>
<p>It is not surprising that the increase in &#x3b1;v&#x3b2;3 integrin activity was triggered by a decrease in &#x3b1;5&#x3b2;1 integrin expression. One plausible explanation for this is a cross-talk process called transdominant inhibition which can occur when two integrins compete for the same cytoplasmic proteins, such as talin-1 or kindlin-2, that activate integrins (<xref ref-type="bibr" rid="B5">Calderwood et al., 2004</xref>). In this scenario, expression of &#x3b1;5&#x3b2;1 integrin inhibits &#x3b1;v&#x3b2;3 integrin because it out competes &#x3b1;v&#x3b2;3 integrin for binding to talin-1 and kindlin-2 (<xref ref-type="fig" rid="F9">Figure 9A</xref>). However, when the levels of the &#x3b1;5&#x3b2;1 integrin decreases, &#x3b1;v&#x3b2;3 integrin is now able to bind talin-1 and kindlin-2 and be activated (<xref ref-type="fig" rid="F9">Figure 9B</xref>) (<xref ref-type="bibr" rid="B50">Lu et al., 2022</xref>; <xref ref-type="bibr" rid="B48">Lolo et al., 2022</xref>; <xref ref-type="bibr" rid="B2">Bouvard et al., 2013</xref>; <xref ref-type="bibr" rid="B53">Moser et al., 2009</xref>). What causes the loss of &#x3b1;5&#x3b2;1 integrin is still unknown. Early studies in fibroblasts have suggested that a change in the expression of transcription factors that control &#x3b1;5&#x3b2;1 integrin expression may be responsible (<xref ref-type="bibr" rid="B26">Gingras et al., 2003</xref>; <xref ref-type="bibr" rid="B27">Gingras et al., 2009</xref>). Alternatively, activation of &#x3b1;v&#x3b2;3 integrin could also be enhanced if the recycling of &#x3b1;5&#x3b2;1 integrins was impaired, thus leading to the rapid and prolonged expression of &#x3b1;v&#x3b2;3 integrin on the cell surface (<xref ref-type="bibr" rid="B6">Caswell et al., 2009</xref>; <xref ref-type="bibr" rid="B1">Arjonen et al., 2012</xref>). These two possibilities are not necessarily mutually exclusive and both processes could be occurring in older tissues.</p>
<fig id="F9" position="float">
<label>FIGURE 9</label>
<caption>
<p>Model of transdominant inhibition of integrin signaling. <bold>(A)</bold> Expression of &#x3b1;5&#x3b2;1 integrin is activated when cytoplasmic proteins such as talin-1 and kindlin-2 bind to its cytoplasmic tails in focal adhesions, triggering the formation of the actomyosin network. Presumably, this leaves those proteins unavailable to bind to &#x3b1;v&#x3b2;3 integrin thus leaving it inactive on the cell surface. <bold>(B)</bold> Loss of &#x3b1;5&#x3b2;1 integrin expression would free these proteins to bind and activate &#x3b1;v&#x3b2;3 integrin. Since &#x3b1;v&#x3b2;3 integrin appears to control &#x3b1;SMA expression, this in turn promotes the incorporation of &#x3b1;SMA into actomyosin networks and the development of the myofibroblast phenotype.</p>
</caption>
<graphic xlink:href="fcell-13-1730542-g009.tif">
<alt-text content-type="machine-generated">Model showing how activity of &#x3b1;5&#x3b2;1 integrin can inhibit &#x3b1;v&#x3b2;3 integrin activity. This process is called transdominant inhibition. Panel A displays an active &#x3b1;5&#x3b2;1 integrin bound to Talin&#x2010;1 and Kindlin&#x2010;2 and linked to actomyosin. The &#x3b1;v&#x3b2;3 integrin is inactive. Panel B shows loss of &#x3b1;5&#x3b2;1 integrin, frees Talin&#x2010;1 and Kindlin-2 to bind and activate the &#x3b1;v&#x3b2;3 integrin.</alt-text>
</graphic>
</fig>
<p>How activation of &#x3b1;v&#x3b2;3 integrin enhances &#x3b1;SMA expression is unclear. &#x3b1;SMA expression in EMT/EndMT is usually thought to occur via enhanced TGF&#x3b2; signaling. Hence, it is not surprising that &#x3b1;v&#x3b2;3 integrin was found to be involved in the development of a mesenchymal phenotype. In TM cells, activation of &#x3b1;v&#x3b2;3 integrin induces the expression of TGF&#x3b2;2 mRNA and protein which is a potent inducer of EMT and EndMT (<xref ref-type="bibr" rid="B21">Filla et al., 2021</xref>). Furthermore, multiple studies show that a synergistic interaction between &#x3b1;v&#x3b2;3 integrin and TGF&#x3b2; signaling triggers the development of a mesenchymal phenotype in a number of different cell types and diseases. For example, this interaction has been shown to be involved in TGF-&#x3b2;-induced EMT in mammary epithelial cells (<xref ref-type="bibr" rid="B25">Galliher and Schiemann, 2006</xref>; <xref ref-type="bibr" rid="B54">Parvani et al., 2015</xref>) possibly through ECM driven &#x3b1;v&#x3b2;3 integrin crosstalk with the TGF&#x3b2; pathway (<xref ref-type="bibr" rid="B3">Brand&#xe3;o-Costa et al., 2020</xref>). More recently correlation analysis between &#x3b2;3 integrin and EMT markers found that &#x3b2;3 integrin expression correlated positively with the mesenchymal biomarkers vimentin, fibronectin, ZEB1, and ZEB2 in lung adenocarcinoma cells. A knockdown of &#x3b1;v&#x3b2;3 integrin in lung cancer cells also led cells reverting back to a partial EMT that was independent of TGF&#x3b2; signaling (<xref ref-type="bibr" rid="B40">Kariya et al., 2021</xref>), again suggesting that EMT may be driven by crosstalk between TGF&#x3b2; and &#x3b1;v&#x3b2;3 integrin. Finally, knockdown of &#x3b1;v&#x3b2;3 integrin suppressed TGF&#x3b2;-induced Notch signaling in human umbilical vein endothelial cells (<xref ref-type="bibr" rid="B74">Wang et al., 2018</xref>) which is also involved in the fibrotic process (<xref ref-type="bibr" rid="B7">Condorelli et al., 2021</xref>; <xref ref-type="bibr" rid="B76">Zhang et al., 2024</xref>).</p>
<p>In conclusion, this study shows that a switch in integrin expression and activity in old TM&#xa0;cells contributes to the development of a mesenchymal phenotype within the TM by upregulating the expression of <italic>&#x3b1;SMA</italic>, <italic>VIM</italic>, <italic>TWIST1</italic>, and <italic>SNAI</italic>2. Ultimately, integrins are likely to play a multi-faceted and essential role in controlling EMT/EndMT in the TM. They regulate cell contractility and adhesion, and are one of the major classes of receptors that respond to mechanoenvironmental cues such as stiffness that are involved in the development of a myofibroblast phenotype and also detected in glaucomatous TM tissues (<xref ref-type="bibr" rid="B46">Last et al., 2011</xref>). They also influence numerous downstream signaling pathways involved in EndMT, including TGF&#x3b2;2 signaling, focal adhesion kinase (FAK)/p21-activated kinase (PAK), Wnt/&#x3b2;-catenin, FAK/glycogen synthase kinase-3&#x3b2; (GSK3&#x3b2;) and ILK/NF-kB (<xref ref-type="bibr" rid="B58">Piera-Velazquez and Jimenez, 2019</xref>). Hence, the role of these integrins in the early development of a mesenchymal phenotype makes them potential targets for therapeutic interventions in the development of POAG.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="s5">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="ethics-statement" id="s6">
<title>Ethics statement</title>
<p>The studies involving human cadaver tissues were approved by the University of Wisconsin and Oregon Health &#x0026; Science University Institutional Review Boards and conducted in accordance to the guidelines outlined by NIH and institutional requirements.</p>
</sec>
<sec sec-type="author-contributions" id="s7">
<title>Author contributions</title>
<p>KJ: Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing &#x2013; review and editing. JF: Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing &#x2013; review and editing. MF: Investigation, Methodology, Validation, Visualization, Writing &#x2013; review and editing. NS: Investigation, Visualization, Writing &#x2013; review and editing. KK: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing &#x2013; original draft, Writing &#x2013; review and editing. DP: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Supervision, Visualization, Writing &#x2013; original draft, Writing &#x2013; review and editing.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We thank Wisconsin Lions Eye Bank and VisionGift, Portland, OR for help with procurement of human cadaver eyes. The authors also wish to thank the University of Wisconsin Translational Research Initiatives in Pathology (TRIP) Laboratory, supported by the UW Department of Pathology and Laboratory Medicine, UWCCC (P30 CA014520) and the Office of The Director- NIH (S10 OD023526) for its histology services.</p>
</ack>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s10">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s11">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1484206/overview">Judith West-Mays</ext-link>, McMaster University, Canada</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/340086/overview">Yiqin Du</ext-link>, University of South Florida, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/672608/overview">Colin E. Willoughby</ext-link>, Ulster University, United Kingdom</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arjonen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alano</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Veltel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ivaska</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Distinct recycling of active and inactive &#x3b2;1 integrins</article-title>. <source>Traffic</source> <volume>13</volume>, <fpage>610</fpage>&#x2013;<lpage>625</lpage>. <pub-id pub-id-type="doi">10.1111/j.1600-0854.2012.01327.x</pub-id>
<pub-id pub-id-type="pmid">22222055</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouvard</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pouwels</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>De Franceschi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ivaska</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Integrin inactivators: balancing cellular functions in vitro and in vivo</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>14</volume>, <fpage>430</fpage>&#x2013;<lpage>442</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3599</pub-id>
<pub-id pub-id-type="pmid">23719537</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brand&#xe3;o-Costa</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Helal-Neto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Barcellos-De-Souza</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Morgado-Diaz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Barja-Fidalgo</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Extracellular matrix derived from high metastatic human breast cancer triggers epithelial-mesenchymal transition in epithelial breast cancer cells through &#x3b1;v&#x3b2;3 integrin</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>2995</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21082995</pub-id>
<pub-id pub-id-type="pmid">32340328</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burridge</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chrzanowska-Wodnicka</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Focal adhesions, contractility, and signaling</article-title>. <source>Ann Rev Cell and Dev Biol</source> <volume>12</volume>, <fpage>463</fpage>&#x2013;<lpage>518</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.cellbio.12.1.463</pub-id>
<pub-id pub-id-type="pmid">8970735</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calderwood</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Tai</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Di Paolo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>De Camilli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ginsberg</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Competition for talin results in trans-dominant inhibition of integrin activation</article-title>. <source>J. Biol. Chem.</source> <volume>279</volume>, <fpage>28889</fpage>&#x2013;<lpage>28895</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M402161200</pub-id>
<pub-id pub-id-type="pmid">15143061</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Caswell</surname>
<given-names>P. T.</given-names>
</name>
<name>
<surname>Vadrevu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Norman</surname>
<given-names>J. C.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Integrins:Masters and slaves of endocytic transport</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>10</volume>, <fpage>843</fpage>&#x2013;<lpage>853</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2799</pub-id>
<pub-id pub-id-type="pmid">19904298</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Condorelli</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Hachem</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Zambruno</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nystrom</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Candi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Castiglia</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Notch-ing up knowledge on molecular mechanisms of skin fibrosis: focus on the multifaceted notch signalling pathway</article-title>. <source>J. Biomed. Sci.</source> <volume>28</volume>, <fpage>36</fpage>. <pub-id pub-id-type="doi">10.1186/s12929-021-00732-8</pub-id>
<pub-id pub-id-type="pmid">33966637</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diaz-Gonzalez</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Forsyth</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Ginsberg</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Trans-dominant inhibition of integrin function</article-title>. <source>Mol. Biol. Cell</source> <volume>7</volume>, <fpage>1939</fpage>&#x2013;<lpage>1951</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.7.12.1939</pub-id>
<pub-id pub-id-type="pmid">8970156</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dupuy</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Caron</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Integrin-dependent phagocytosis: spreading from microadhesion to new concepts</article-title>. <source>J. Cell Sci.</source> <volume>121</volume>, <fpage>1773</fpage>&#x2013;<lpage>1783</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.018036</pub-id>
<pub-id pub-id-type="pmid">18492791</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ehrlich</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Burke-Conte</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wittenborn</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Saaddine</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Omura</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Friedman</surname>
<given-names>D. S.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Prevalence of glaucoma among US adults in 2022</article-title>. <source>JAMA Ophthalmol.</source> <volume>142</volume>, <fpage>1046</fpage>&#x2013;<lpage>1053</lpage>. <pub-id pub-id-type="doi">10.1001/jamaophthalmol.2024.3884</pub-id>
<pub-id pub-id-type="pmid">39418040</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Hultgren</surname>
<given-names>N. W.</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>C. C. W.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Regulation of partial and reversible endothelial-to-mesenchymal transition in angiogenesis</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>9</volume>, <fpage>702021</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2021.702021</pub-id>
<pub-id pub-id-type="pmid">34692672</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Gagen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Crotti</surname>
<given-names>T. N.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Dexamethasone increases &#x3b1;v&#x3b2;3 integrin expression and affinity through a calcineurin/NFAT pathway</article-title>. <source>BBA- Mol. Cell Res.</source> <volume>1833</volume>, <fpage>3306</fpage>&#x2013;<lpage>3313</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2013.09.020</pub-id>
<pub-id pub-id-type="pmid">24100160</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2019a</year>). <article-title>Effect of &#x3b1;v&#x3b2;3 integrin expression and activity on intraocular pressure (IOP)</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>60</volume>, <fpage>1776</fpage>&#x2013;<lpage>1788</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.18-26038</pub-id>
<pub-id pub-id-type="pmid">31022732</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2019b</year>). <article-title>Role of fibronectin in primary open angle glaucoma</article-title>. <source>Cells</source> <volume>8</volume>, <fpage>1518</fpage>. <pub-id pub-id-type="doi">10.3390/cells8121518</pub-id>
<pub-id pub-id-type="pmid">31779192</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Integrin crosstalk and its effect on the biological functions of the trabecular meshwork/Schlemm&#x27;s canal</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>10</volume>, <fpage>886702</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2022.886702</pub-id>
<pub-id pub-id-type="pmid">35573686</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Role of integrins in the development of fibrosis in the trabecular meshwork</article-title>. <source>Front. Ophthalmol.</source> <volume>3</volume>, <fpage>1274797</fpage>. <pub-id pub-id-type="doi">10.3389/fopht.2023.1274797</pub-id>
<pub-id pub-id-type="pmid">38983065</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Woods</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>&#x392;1 and &#x3b2;3 integrins cooperate to induce syndecan-4-containing cross-linked actin networks in human trabecular meshwork cells</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>47</volume>, <fpage>1956</fpage>&#x2013;<lpage>1967</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.05-0626</pub-id>
<pub-id pub-id-type="pmid">16639003</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schwinn</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Sheibani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kaufman</surname>
<given-names>P. L.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Regulation of cross-linked actin network (CLAN) formation in human trabecular meshwork (HTM) cells by convergence of distinct &#x3b2;1 and &#x3b2;3 integrin pathways</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>50</volume>, <fpage>5723</fpage>&#x2013;<lpage>5731</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.08-3215</pub-id>
<pub-id pub-id-type="pmid">19643963</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Peotter</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The role of integrins in glaucoma</article-title>. <source>Exp. Eye Res.</source> <volume>158</volume>, <fpage>124</fpage>&#x2013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1016/j.exer.2016.05.011</pub-id>
<pub-id pub-id-type="pmid">27185161</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filla</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Desikan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Peotter</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Wannow</surname>
<given-names>A. C.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Activation of &#x3b1;v&#x3b2;3 integrin alters fibronectin fibril formation in human trabecular meshwork cells in a Rock-independent manner</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>60</volume>, <fpage>3897</fpage>&#x2013;<lpage>3913</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.19-27171</pub-id>
<pub-id pub-id-type="pmid">31529121</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Meyers</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Overexpression and activation of &#x3b1;v&#x3b2;3 integrin differentially affects TGF&#x3b2;2 signaling in human trabecular meshwork cells</article-title>. <source>Cells</source> <volume>10</volume>, <fpage>1923</fpage>. <pub-id pub-id-type="doi">10.3390/cells10081923</pub-id>
<pub-id pub-id-type="pmid">34440692</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Dunn</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>NFATc1 regulation of dexamethasone-induced TGF&#x3b2;2 expression is cell cycle dependent in trabecular meshwork cell</article-title>. <source>Cells</source> <volume>12</volume>, <fpage>504</fpage>. <pub-id pub-id-type="doi">10.3390/cells12030504</pub-id>
<pub-id pub-id-type="pmid">36766846</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuchshofer</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tamm</surname>
<given-names>E. R.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>The role of TGF&#x2212;&#x3b2; in the pathogenesis of primary open-angle glaucoma</article-title>. <source>Cell Tissue Res.</source> <volume>347</volume>, <fpage>279</fpage>&#x2013;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1007/s00441-011-1274-7</pub-id>
<pub-id pub-id-type="pmid">22101332</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gagen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liton</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Activated &#x3b1;v&#x3b2;3 integrin regulates &#x3b1;v&#x3b2;5 integrin-mediated phagocytosis in trabecular meshwork cells</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>54</volume>, <fpage>5000</fpage>&#x2013;<lpage>5011</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.13-12084</pub-id>
<pub-id pub-id-type="pmid">23821196</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galliher</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Schiemann</surname>
<given-names>W. P.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>&#x392;3 integrin and src facilitate transforming growth factor-&#x3b2; mediated induction of epithelial-mesenchymal transition in mammary epithelial cells</article-title>. <source>Breast Cancer Res.</source> <volume>8</volume>, <fpage>R42</fpage>. <pub-id pub-id-type="doi">10.1186/bcr1524</pub-id>
<pub-id pub-id-type="pmid">16859511</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gingras</surname>
<given-names>M.-E.</given-names>
</name>
<name>
<surname>Larouche</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Larouche</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Leclerc</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Salesse</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guerin</surname>
<given-names>S. L.</given-names>
</name>
</person-group> (<year>2003</year>). <article-title>Regulation of the integrin subunit alpha5 gene promoter by the transcription factors Sp1/Sp3 is influenced by the cell density in rabbit corneal epithelial cells</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>44</volume>, <fpage>3742</fpage>&#x2013;<lpage>3755</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.03-0191</pub-id>
<pub-id pub-id-type="pmid">12939287</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gingras</surname>
<given-names>M.-E.</given-names>
</name>
<name>
<surname>Masson-Gadais</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zaniolo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Leclerc</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Drouin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Germain</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Differential binding of the transcription factors Sp1, AP-1, and NFI to the promoter of the human alpha5 integrin gene dictates its transcriptional activity</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>50</volume>, <fpage>57</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.08-2059</pub-id>
<pub-id pub-id-type="pmid">18775869</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goffin</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Pittet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Csucs</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lussi</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Meister</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Hinz</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Focal adhesion size controls tension-dependent recruitment of &#x3b1;-smooth muscle actin to stress fibers</article-title>. <source>J. Biol. Chem.</source> <volume>172</volume>, <fpage>259</fpage>&#x2013;<lpage>268</lpage>. <pub-id pub-id-type="doi">10.1083/jcb.200506179</pub-id>
<pub-id pub-id-type="pmid">16401722</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hennig</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kuespert</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Haunberger</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Goepferich</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fuchshofer</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Cyclic RGD peptides target human trabecular meshwork cells while ameliorating connective tissue growth factor-induced fibrosis</article-title>. <source>J. Drug Target</source> <volume>24</volume>, <fpage>952</fpage>&#x2013;<lpage>959</lpage>. <pub-id pub-id-type="doi">10.3109/1061186X.2016.1163709</pub-id>
<pub-id pub-id-type="pmid">26973018</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinz</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>The myofibroblast: Paradigm for a mechanically active cell</article-title>. <source>J. Biomech.</source> <volume>43</volume>, <fpage>146</fpage>&#x2013;<lpage>155</lpage>. <pub-id pub-id-type="doi">10.1016/j.jbiomech.2009.09.020</pub-id>
<pub-id pub-id-type="pmid">19800625</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gabbiani</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Fibrosis: recent advances in myofibroblast biology and new therapeutic perspectives</article-title>. <source>F1000 Biol. Rep.</source> <volume>2</volume>, <fpage>78</fpage>. <pub-id pub-id-type="doi">10.3410/B2-78</pub-id>
<pub-id pub-id-type="pmid">21170369</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Phan</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Thannickal</surname>
<given-names>V. J.</given-names>
</name>
<name>
<surname>Prunotto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Desmouliere</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Varga</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Recent developments in myofibroblast biology: paradigms for connective tissue remodeling</article-title>. <source>Am. J. Path</source> <volume>180</volume>, <fpage>1340</fpage>&#x2013;<lpage>1355</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2012.02.004</pub-id>
<pub-id pub-id-type="pmid">22387320</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hinz</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mcculloch</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Coelho</surname>
<given-names>N. M.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Mechanical regulation of myofibroblast phenoconversion and collagen contraction</article-title>. <source>Exp. Cell Res.</source> <volume>379</volume>, <fpage>119</fpage>&#x2013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2019.03.027</pub-id>
<pub-id pub-id-type="pmid">30910400</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Islam</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bostr&#xf6;m</surname>
<given-names>K. I.</given-names>
</name>
<name>
<surname>Di Carlo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Tintut</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The mechanobiology of endothelial-to-mesenchymal transition in cardiovascular disease</article-title>. <source>Front. Physiol.</source> <volume>12</volume>, <fpage>734215</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2021.734215</pub-id>
<pub-id pub-id-type="pmid">34566697</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johns</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Filla</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>K. E.</given-names>
</name>
<etal/>
</person-group> (<year>2025</year>). <article-title>Age-related dysregulation of &#x3b1;5&#x3b2;1 and &#x3b1;v&#x3b2;3 integrin activity alters contractile properties of trabecular meshwork cells</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>66</volume>, <fpage>31</fpage>. <pub-id pub-id-type="doi">10.1167/iovs.66.6.31</pub-id>
<pub-id pub-id-type="pmid">40488712</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnstone</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>R. K.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Aqueous outflow regulation &#x2013; 21st century concepts</article-title>. <source>Prog. Retin Eye Res.</source> <volume>83</volume>, <fpage>100917</fpage>. <pub-id pub-id-type="doi">10.1016/j.preteyeres.2020.100917</pub-id>
<pub-id pub-id-type="pmid">33217556</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ehrlich</surname>
<given-names>H. P.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Fibroblast expression of &#x3b1;-smooth muscle actin, &#x3b1;2&#x3b2;1 integrin and &#x3b1;v&#x3b2;3 integrin: influence of surface rigidity</article-title>. <source>Exp. Mol. Pathol.</source> <volume>91</volume>, <fpage>394</fpage>&#x2013;<lpage>399</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexmp.2011.04.007</pub-id>
<pub-id pub-id-type="pmid">21530503</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Junglas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>A. H. L.</given-names>
</name>
<name>
<surname>Welge-Lussen</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Tamm</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fuchshofer</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Connective tissue growth factor induces extracellular matrix deposition in human trabecular meshwork cells</article-title>. <source>Exp. Eye Res.</source> <volume>88</volume>, <fpage>1065</fpage>&#x2013;<lpage>1075</lpage>. <pub-id pub-id-type="doi">10.1016/j.exer.2009.01.008</pub-id>
<pub-id pub-id-type="pmid">19450452</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Junglas</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kuespert</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Seleem</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Struller</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ullmann</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bosl</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork</article-title>. <source>Am. J. Pathol.</source> <volume>180</volume>, <fpage>2386</fpage>&#x2013;<lpage>2403</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2012.02.030</pub-id>
<pub-id pub-id-type="pmid">22542845</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kariya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Oyama</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Suzuki</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Kariya</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>&#x3b1;v&#x3b2;3 integrin induces partial emt independent of TGF-&#x3b2; signaling</article-title>. <source>Comms Biol.</source> <volume>4</volume>, <fpage>490</fpage>. <pub-id pub-id-type="doi">10.1038/s42003-021-02003-6</pub-id>
<pub-id pub-id-type="pmid">33883697</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kechagia</surname>
<given-names>J. Z.</given-names>
</name>
<name>
<surname>Ivaska</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Roca-Cusachs</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Integrins as biomechanical sensors of the microenvironment</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>20</volume>, <fpage>457</fpage>&#x2013;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1038/s41580-019-0134-2</pub-id>
<pub-id pub-id-type="pmid">31182865</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keller</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Pathogenesis of glaucoma: extracellular matrix dysfunction in the trabecular meshwork&#x2014;A review</article-title>. <source>Clin. Exp. Ophthalmol.</source> <volume>50</volume>, <fpage>163</fpage>&#x2013;<lpage>182</lpage>. <pub-id pub-id-type="doi">10.1111/ceo.14027</pub-id>
<pub-id pub-id-type="pmid">35037377</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keller</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Borr&#xe1;s</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Brunner</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Chansangpetch</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>A. F.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Consensus recommendations for trabecular meshwork cell isolation, characterization and culture</article-title>. <source>Exp. Eye Res.</source> <volume>171</volume>, <fpage>164</fpage>&#x2013;<lpage>173</lpage>. <pub-id pub-id-type="doi">10.1016/j.exer.2018.03.001</pub-id>
<pub-id pub-id-type="pmid">29526795</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ginsberg</surname>
<given-names>M. H.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Regulation of integrin activation</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source> <volume>27</volume>, <fpage>321</fpage>&#x2013;<lpage>345</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-100109-104104</pub-id>
<pub-id pub-id-type="pmid">21663444</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lamouille</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Derynck</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Molecular mechanisms of epithelial&#x2013;mesenchymal transition</article-title>. <source>Nat. Rev. Mol. Cell Biol.</source> <volume>15</volume>, <fpage>178</fpage>&#x2013;<lpage>196</lpage>. <pub-id pub-id-type="doi">10.1038/nrm3758</pub-id>
<pub-id pub-id-type="pmid">24556840</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Last</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Reilly</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Acott</surname>
<given-names>T. S.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Elastic modulus determination of normal and glaucomatous human trabecular meshwork</article-title>. <source>Invest. Ophthamol Vis. Sci.</source> <volume>52</volume>, <fpage>2147</fpage>&#x2013;<lpage>2152</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.10-6342</pub-id>
<pub-id pub-id-type="pmid">21220561</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Raghunathan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Stamer</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Ganapathy</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Herberg</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Extracellular matrix stiffness and TGF&#x3b2;2 regulate yap/taz activity in human trabecular meshwork cells</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>10</volume>, <fpage>844342</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2022.844342</pub-id>
<pub-id pub-id-type="pmid">35300422</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lolo</surname>
<given-names>F.-N.</given-names>
</name>
<name>
<surname>Pav&#xf3;n</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Grande-Garc&#xed;a</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Elosegui-Artola</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Segatori</surname>
<given-names>V. I.</given-names>
</name>
<name>
<surname>S&#xe1;nchez</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Caveolae couple mechanical stress to integrin recycling and activation</article-title>. <source>eLife</source> <volume>11</volume>, <fpage>e82348</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.82348</pub-id>
<pub-id pub-id-type="pmid">36264062</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lovisa</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fletcher-Sananikone</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hensel</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lahiri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hertig</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Endothelial-to-mesenchymal transition compromises vascular integrity to induce myc-mediated metabolic reprogramming in kidney fibrosis</article-title>. <source>Sci. Signal</source> <volume>13</volume>, <fpage>eaaz2597</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.aaz2597</pub-id>
<pub-id pub-id-type="pmid">32518142</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bromberger</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Mechanism of integrin activation by talin and its cooperation with kindlin</article-title>. <source>Nat. Commun.</source> <volume>13</volume>, <fpage>2362</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-022-30117-w</pub-id>
<pub-id pub-id-type="pmid">35488005</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machado-Costa</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Helal-Neto</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Vieira</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Barcellos-De-Souza</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Morgado-Diaz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Barja-Fidalgo</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Extracellular matrix derived from high metastatic human breast cancer triggers epithelial-mesenchymal transition in epithelial breast cancer cells through &#x3b1;v&#x3b2;3 integrin</article-title>. <source>Int. J. Mol. Sci.</source> <volume>21</volume>, <fpage>2992</fpage>.<pub-id pub-id-type="pmid">32340284</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Madamanchi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zijlstra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zutter</surname>
<given-names>M. M.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Flipping the switch: integrin switching provides metastatic competence</article-title>. <source>Sci. Signal</source> <volume>7</volume> (<issue>318</issue>), <fpage>pe9</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.2005236</pub-id>
<pub-id pub-id-type="pmid">24667375</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Legate</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Zent</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Fassler</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>The tail of integrins, talin and kindlins</article-title>. <source>Sci</source> <volume>324</volume>, <fpage>895</fpage>&#x2013;<lpage>899</lpage>. <pub-id pub-id-type="doi">10.1126/science.1163865</pub-id>
<pub-id pub-id-type="pmid">19443776</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parvani</surname>
<given-names>J. G.</given-names>
</name>
<name>
<surname>Gujrati</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Mack</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Schiemann</surname>
<given-names>W. P.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>Z. R.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Silencing &#x3b2;3 integrin by targeted ECO/siRNA nanoparticles inhibits emt and metastasis of triple-negative breast cancer</article-title>. <source>Cancer Res.</source> <volume>75</volume>, <fpage>2316</fpage>&#x2013;<lpage>2325</lpage>. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3485</pub-id>
<pub-id pub-id-type="pmid">25858145</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pattabiraman</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Hic-5 regulates actin cytoskeletal reorganization and expression of fibrogenic markers and myocilin in trabecular meshwork cells</article-title>. <source>Invest. Ophthamol Vis. Sci.</source> <volume>56</volume>, <fpage>5656</fpage>&#x2013;<lpage>5669</lpage>. <pub-id pub-id-type="doi">10.1167/iovs.15-17204</pub-id>
<pub-id pub-id-type="pmid">26313302</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peotter</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Phillips</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dimeo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>J. M.</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Involvement of Tiam1, Rhog, Elmo/Ilk and Rac1-mediated phagocytosis in human trabecular meshwork cells</article-title>. <source>Exp. Eye Res.</source> <volume>347</volume>, <fpage>301</fpage>&#x2013;<lpage>311</lpage>. <pub-id pub-id-type="doi">10.1016/j.yexcr.2016.08.009</pub-id>
<pub-id pub-id-type="pmid">27539661</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Picht</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Welge-Lussen</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Grehn</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>L&#xfc;tjen-Drecoll</surname>
<given-names>E.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Transforming growth factor &#x3b2;2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development</article-title>. <source>Graefe&#x2019;s Arch. Clin. Exp. Ophthalmol.</source> <volume>239</volume>, <fpage>199</fpage>&#x2013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1007/s004170000252</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piera-Velazquez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>S. A.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Endothelial to mesenchymal transition: role in physiology and in the pathogenesis of human diseases</article-title>. <source>Physiol. Rev.</source> <volume>99</volume>, <fpage>1281</fpage>&#x2013;<lpage>1324</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00021.2018</pub-id>
<pub-id pub-id-type="pmid">30864875</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prunotto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bruschi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gunning</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gabbani</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Weibel</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ghiggeri</surname>
<given-names>G. M.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Stable incorporation of &#x3b1;-smooth muscle actin into stress fibers is dependent on specific tropomyosin isoforms</article-title>. <source>Cytoskeleton</source> <volume>72</volume>, <fpage>257</fpage>&#x2013;<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1002/cm.21230</pub-id>
<pub-id pub-id-type="pmid">26147585</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapisarda</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Borghesan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Miguela</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Encheva</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Snijders</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Lujambio</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Integrin beta-3 regulates cellular senescence by activating the TGF-&#x3b2; pathway</article-title>. <source>Cell Rep.</source> <volume>18</volume>, <fpage>2480</fpage>&#x2013;<lpage>2493</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2017.02.012</pub-id>
<pub-id pub-id-type="pmid">28273461</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roca-Cusachs</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Iskratsch</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sheetz</surname>
<given-names>M. P.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Finding the weakest link - exploring integrin-mediated mechanical molecular pathways</article-title>. <source>J. Cell Sci.</source> <volume>125</volume>, <fpage>3025</fpage>&#x2013;<lpage>3038</lpage>. <pub-id pub-id-type="doi">10.1242/jcs.095794</pub-id>
<pub-id pub-id-type="pmid">22797926</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoenwaelder</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Burridge</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Bidirectional signaling between the cytoskeleton and integrins</article-title>. <source>Curr. Opin. Cell Biol.</source> <volume>11</volume>, <fpage>274</fpage>&#x2013;<lpage>286</lpage>. <pub-id pub-id-type="doi">10.1016/s0955-0674(99)80037-4</pub-id>
<pub-id pub-id-type="pmid">10209151</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Selman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pardo</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Fibroageing: an ageing pathological feature driven by dysregulated extracellular matrix-cell mechanobiology</article-title>. <source>Ageing Res. Rev.</source> <volume>70</volume>, <fpage>101393</fpage>. <pub-id pub-id-type="doi">10.1016/j.arr.2021.101393</pub-id>
<pub-id pub-id-type="pmid">34139337</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Carraher</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Schwarzbauer</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Assembly of fibronectin extracellular matrix</article-title>. <source>Annu. Rev. Cell Dev. Biol.</source> <volume>26</volume>, <fpage>397</fpage>&#x2013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-100109-104020</pub-id>
<pub-id pub-id-type="pmid">20690820</pub-id>
</mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamer</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Acott</surname>
<given-names>T. S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Current understanding of conventional outflow dysfunction in glaucoma</article-title>. <source>Curr. Opinon Ophthalmol.</source> <volume>23</volume>, <fpage>135</fpage>&#x2013;<lpage>143</lpage>. <pub-id pub-id-type="doi">10.1097/ICU.0b013e32834ff23e</pub-id>
<pub-id pub-id-type="pmid">22262082</pub-id>
</mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stamer</surname>
<given-names>W. D.</given-names>
</name>
<name>
<surname>Braakman</surname>
<given-names>S. T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Ethier</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Fredberg</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Overby</surname>
<given-names>D. R.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Biomechanics of schlemm&#x2019;s canal endothelium and intraocular pressure reduction</article-title>. <source>Prog. Retin. Eye Res.</source> <volume>44</volume>, <fpage>86</fpage>&#x2013;<lpage>98</lpage>. <pub-id pub-id-type="doi">10.1016/j.preteyeres.2014.08.002</pub-id>
<pub-id pub-id-type="pmid">25223880</pub-id>
</mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hamlin</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Schwarzbauer</surname>
<given-names>J. E.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Fibronectin matrix assembly at a glance</article-title>. <source>J. Cell Sci.</source> <volume>138</volume>, <fpage>263834</fpage>. <pub-id pub-id-type="doi">10.1242/jcs.263834</pub-id>
<pub-id pub-id-type="pmid">40130407</pub-id>
</mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Kelber</surname>
<given-names>J. A.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Aqueous humor TGF&#x3b2; and fbrillin-1 in tsk mice reveal clues to poag pathogenesis</article-title>. <source>Sci. Rep.</source> <volume>14</volume>, <fpage>3517</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-024-53659-z</pub-id>
<pub-id pub-id-type="pmid">38347040</pub-id>
</mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Anfinogenova</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Physiologic properties and regulation of the actin cytoskeleton in vascular smooth muscle</article-title>. <source>J. Cardiovasc. Pharmacol Ther</source> <volume>13</volume>, <fpage>130</fpage>&#x2013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1177/1074248407313737</pub-id>
<pub-id pub-id-type="pmid">18212360</pub-id>
</mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tham</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>T. Y.</given-names>
</name>
<name>
<surname>Quigley</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Aung</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>C.-Y.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis</article-title>. <source>Ophthalmol</source> <volume>121</volume>, <fpage>2081</fpage>&#x2013;<lpage>2090</lpage>. <pub-id pub-id-type="doi">10.1016/j.ophtha.2014.05.013</pub-id>
<pub-id pub-id-type="pmid">24974815</pub-id>
</mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tripathi</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>W. F.</given-names>
</name>
<name>
<surname>Tripathi</surname>
<given-names>B. J.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Aqueous humor in glaucomatous eyes contains an increased level of TGF-&#x3b2;2</article-title>. <source>Exp. Eye Res.</source> <volume>59</volume>, <fpage>723</fpage>&#x2013;<lpage>727</lpage>. <pub-id pub-id-type="doi">10.1006/exer.1994.1158</pub-id>
<pub-id pub-id-type="pmid">7698265</pub-id>
</mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Truong</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ghotra</surname>
<given-names>V. P. S.</given-names>
</name>
<name>
<surname>Nirmala</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Haazen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Le Devedec</surname>
<given-names>S. E.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>&#x392;1 integrin inhibition elicits a prometastatic switch through the TGF&#x3b2;-mir-200-Zeb network in E-cadherin-positive triple-negative breast cancer</article-title>. <source>Sci. Signal</source> <volume>7</volume>, <fpage>ra15</fpage>. <pub-id pub-id-type="doi">10.1126/scisignal.2004751</pub-id>
<pub-id pub-id-type="pmid">24518294</pub-id>
</mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Zyl</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Mcadams</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>Y.-R.</given-names>
</name>
<name>
<surname>Shekhar</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Regev</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Cell atlas of aqueous humor outflow pathways in eyes of humans and four model species provides insight into glaucoma pathogenesis</article-title>. <source>Proc. Natl. Acad. Sci. U. S. A.</source> <volume>117</volume>, <fpage>10339</fpage>&#x2013;<lpage>10349</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2001250117</pub-id>
<pub-id pub-id-type="pmid">32341164</pub-id>
</mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Integrin &#x3b2;3 mediates the endothelial-to-mesenchymal transition via the notch pathway</article-title>. <source>Cell Physiol. Biochem.</source> <volume>49</volume>, <fpage>985</fpage>&#x2013;<lpage>997</lpage>. <pub-id pub-id-type="doi">10.1159/000493229</pub-id>
<pub-id pub-id-type="pmid">30196283</pub-id>
</mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.-F.</given-names>
</name>
<name>
<surname>Holden</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Faralli</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>K. E.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Fibrosis-related gene expression in normal and glaucomatous trabecular meshwork cells</article-title>. <source>Invest. Ophthalmol. Vis. Sci.</source> <volume>66</volume>, <fpage>48</fpage>. <pub-id pub-id-type="doi">10.1167/iovs.66.3.48</pub-id>
<pub-id pub-id-type="pmid">40126508</pub-id>
</mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Notch signaling regulates pulmonary fibrosis</article-title>. <source>Front. Cell Dev. Biol.</source> <volume>12</volume>, <fpage>1450038</fpage>. <pub-id pub-id-type="doi">10.3389/fcell.2024.1450038</pub-id>
<pub-id pub-id-type="pmid">39450276</pub-id>
</mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Maruyama</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>E. L.</given-names>
</name>
<name>
<surname>Yue</surname>
<given-names>B. Y. J. T.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Expression of integrin receptors in the human trabecular meshwork</article-title>. <source>Curr. Eye Res.</source> <volume>19</volume>, <fpage>395</fpage>&#x2013;<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1076/ceyr.19.5.395.5297</pub-id>
<pub-id pub-id-type="pmid">10520215</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</article>